

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

In re:

AMYRIS, INC.,

Debtors.<sup>1</sup>

Chapter 11

Case No. 23-11131 (TMH)

(Jointly Administered)

Related Docket No. 1170

**DECLARATION OF BRADLEY M. ORELOWITZ IN SUPPORT OF  
CONFIRMATION OF THIRD AMENDED JOINT CHAPTER 11 PLAN OF  
REORGANIZATION OF AMYRIS, INC. AND ITS AFFILIATED DEBTORS  
UNDER CHAPTER 11 OF THE BANKRUPTCY CODE**

I, Bradley M. Orelowitz, pursuant to section 1726 of title 28 of the United States Code, hereby declare that the following is true to the best of my knowledge, information, and belief:

**Background and Qualifications**

1. I am a Managing Director of Back Bay Management Corporation and its division, The Michel-Shaked Group (“MSG”). MSG’s professionals have extensive experience in the analysis of solvency, capital surplus, and valuation of public and privately-held businesses, including businesses that are complex, international organizations. Experts at MSG have been engaged in numerous cases, including: *Adelphia Communications, Air Transport International, Belle Casinos, Bennett Funding Group, Bike Athletic, Boston Chicken, Caesars Entertainment, Caldor Corporation, Carleton Woolen Mills, Cascade International, Chesapeake Energy, Chinos Holdings (J. Crew), Congoleum, Dade Behring Holdings, Diet Center, Duro Industries, Enron, Enstar Group, Flintkote, FoxMeyer Corporation, Halliburton, Hayes Lemmerz International, Hechinger Company, Home Insurance, Jones Trucking Lines, Lady Luck Gaming, Laminate Kingdom, Lernout & Hauspie, Loyalty*

<sup>1</sup> A complete list of each of the Debtors in these Chapter 11 Cases may be obtained on the website of the Debtors’ claims and noticing agent at <https://cases.stretto.com/amyris>. The location of Debtor Amyris Inc.’s principal place of business and the Debtors’ service address in these Chapter 11 Cases is 5885 Hollis Street, Suite 100, Emeryville, CA 94608.

*Ventures, M4 Environmental, Medley, Merry-Go-Round, MGM/UA Communications, Mirant, Mortgages Limited, Munford Inc. (d/b/a Majik Market), Neiman Marcus, NetFax, Nine West, North Manchester Foundry, OneStar Long Distance, Payless ShoeSource (2017 and 2019), Quadrax, Quigly, Raytech Corporation, Refco, Safety-Kleen, Shoebuy.com, Specialty Retail Shops Holding Corp. (d/b/a ShopKo), Smurfit-Stone Container, Solar Cosmetic Labs, Stone & Webster, Styling Technology Corporation, Tailored Brands, Telecom Argentina, The Limited, Tribune Company, United Companies Financials, Vencor, and Vetta Sports.*

2. For over 30 years, I have provided business consulting services to boards of directors, investors, shareholders, law firms and governmental agencies nationwide, including more than 20 years with MSG. Prior to joining MSG, I was the Chief Financial Officer of a retail business, and an Audit Manager for a public accounting firm. My practice at MSG focuses on valuation, bankruptcy, damages, accounting, securities, capital markets, employment, and pensions and retirement plan issues.

3. I have performed valuations, solvency and damages analyses in numerous industries including cable, drug distribution, education, energy, financial services, health care, industrial, insurance, leisure, manufacturing, media, medical, pharmaceuticals, real estate, retail, software, sports franchises, technology, telecommunications, tire & rubber and tobacco. Some of the engagements I have been retained on include the largest bankruptcies, securities fraud, and pension litigation cases in U.S. history. A significant number of my assignments involved financial distress, restructuring, solvency and other bankruptcy-related consulting.

4. I have written on topics such as valuation, bankruptcy, pension and ERISA issues. I am a Member of the American Institute of Certified Public Accountants (AICPA) and the American Bankruptcy Institute (ABI) and have contributed several articles on valuation and bankruptcy to the ABI Journal, a monthly publication to the over 12,000 members of the ABI.

I have also spoken on various panels at industry conferences, delivered seminars to law firms and have taught, as a guest lecturer, business school classes on valuation.

5. I have a Bachelor of Commerce with Accounting and Auditing majors and a Bachelor of Accounting Science – Honors from the University of South Africa. I also have a Master of Business Administration (High Honors) from Boston University and am a Certified Public Accountant, registered in the Commonwealth of Massachusetts. A copy of my curriculum vitae is attached hereto as Exhibit 1.

6. On December 7, 2023, the Court entered its *Order Authorizing the Retention and Employment of Back Bay Management Corporation and Its Division, The Michel-Shaked Group, as Expert Consultant, Effective as of October 31, 2023* [Docket No. 844] (the “MSG Retention Order”). In connection with its retention in this matter, MSG has conducted an enterprise valuation of Amyris, Inc. and its affiliated debtors (“Amyris”) on a going concern basis, as well as a valuation of Amyris’ intellectual property assets.

7. I submit this Declaration in support of confirmation of the *Third Amended Joint Chapter 11 Plan of Reorganization of Amyris, Inc. and Its Affiliated Debtors Under Chapter 11 of the Bankruptcy Code* (as modified, amended, or supplemented from time to time, the “Plan”).<sup>2</sup>

8. Neither MSG nor I is being specifically compensated for this testimony, other than compensation to MSG as a professional services firm retained by Amyris pursuant to the MSG Retention Order. In accordance with recognized professional ethics, my professional fees, or those of personnel working under my direction at MSG for this testimony are not contingent upon the

---

<sup>2</sup> Capitalized terms used but not otherwise defined herein have the meanings ascribed to them in the Plan or in *Debtors’ Memorandum of Law in Support of Confirmation of Plan of Reorganization of Amyris, Inc. and Its Affiliated Debtors Under Chapter 11 of the Bankruptcy Code, and Omnibus Reply to Objections*, as applicable.

opinions expressed herein, and MSG does not have a present or intended financial interest in the outcome of this matter.

9. The statements in this Declaration are, except where specifically noted, based on my personal knowledge or opinion, on information that I have received from Amyris' employees or advisors, or employees of MSG working directly with me or under my supervision, direction, or control. If called to testify, I could and would testify as to the facts and opinions set forth herein.

### **Summary of Expert Opinions**

10. It is my opinion that, as of August 9, 2023, the date that Amyris filed for bankruptcy, Amyris' enterprise value was \$134.4 million. For Amyris' go-forward business, I utilized the Discounted Cash Flow ("DCF") valuation methodology to arrive at a value of \$105.2 million. The DCF calculation is based on Amyris' financial projections for fiscal years 2024 – 2028 that reflect "Amyris 2.0," which represent the reorganized company (the "Disclosure Statement Financial Projections").<sup>3</sup> To this value I added the proceeds expected to be received by Amyris from the sale of its consumer brands businesses in the amount of \$29.2 million, for a total of \$134.4 million.

11. It is my opinion that, as of August 9, 2023, the value of certain of Amyris' patents, trade secrets, know how, brands, and trademarks that were in place as of March 5, 2019 (the "Amyris IP")<sup>4</sup> was \$27.1 million. It is further my expert opinion that, as of August 9, 2023, the

---

<sup>3</sup> "Amyris 2.0" is described on page 19 of the Amended Disclosure Statement filed December 12, 2023 [Docket No. 893]. The Disclosure Statement Projections are set forth in the Amended Disclosure Statement, Exhibit E, p. 4 [Docket No. 893-5] and the supporting financial model "Phoenix-BP Model\_10.10.23.xls." The Disclosure Statement Projections do not incorporate the restructuring costs incurred by Amyris from its bankruptcy filing to December 31, 2023.

<sup>4</sup> Exhibit 2 to this Declaration sets forth an overview description of the Amyris IP (which includes the following: IP Generating Ingredients Revenue, IP Generating Licensing Revenue, Previously Licensed IP Generating Ingredients Revenue, Previously Licensed IP Not Generating Ingredients Revenue, and Brand Names and Trademarks). As set forth on Exhibit 2, Amyris generates value through the use of its patents in manufacturing ingredients made with

intellectual property relating to technology that has been licensed to third-parties pursuant to research and collaboration agreements and/or in perpetuity for the fields of use that are contemplated in the Disclosure Statement Projections (“Previously Licensed IP Generating Ingredients Revenue”) have no value to Amyris.

12. It is my opinion that, as of August 9, 2023, the value of certain of the Amyris consumer brands business trademarks, brand names and service marks (the “Consumer Brands IP”)<sup>5</sup> was \$9.4 million.

13. It is my expert opinion that, based on the Disclosure Statement Projections,<sup>6</sup> from the petition date (August 9, 2023) to Amyris’ expected emergence from bankruptcy (February 9, 2024), Amyris’ enterprise value, the value of the Amyris IP, the value of Previously Licensed IP Generating Ingredients Revenue, and the value of the Consumer Brands IP will not be materially different.

### **Enterprise Valuation**

14. As shown in the table below, I determined that the enterprise value of Amyris as of August 9, 2023 is \$134.4 million. It is my opinion that from August 9, 2023 to February 9, 2024, Amyris’ enterprise value will not be materially different.<sup>7</sup>

---

synthetic biology, it does not rely on its brand names and trademarks to create value. Therefore, the value of its brand name and trademarks is *de minimis*. Exhibit 3 to this Declaration lists the Amyris patents included in the Amyris IP.

<sup>5</sup> Exhibit 4 to this Declaration lists the trademarks and service marks included in the Consumer Brands IP.

<sup>6</sup> The Disclosure Statement Projections do not incorporate the restructuring costs incurred by the company from its bankruptcy filing to December 31, 2023.

<sup>7</sup> (1) Amyris – Consumer Brands Proceeds.xlsx.

(\$ millions)	Enterprise Value as of August 9, 2023	
Amyris Inc.		
Amyris' Go-Forward Business	\$	105.2
Expected Proceeds from Sale of Consumer Brands (1)		29.2
<b>Concluded Enterprise Value of Amyris Inc.</b>	<b>\$</b>	<b>134.4</b>

15. My enterprise value calculation is based on the fair market value standard, which is defined as: “The price at which the property would change hands between a willing buyer and a willing seller when the former is not under any compulsion to buy and the latter is not under any compulsion to sell, both parties having reasonable knowledge of relevant facts.”<sup>8</sup>

16. The enterprise value for Amyris’ go-forward business was calculated utilizing the DCF methodology. The DCF methodology is a standard framework used by financial professionals for valuing a business. The DCF process estimates a stream of cash flows over a projection period and then discounts the stream by a discount rate back to the valuation date. A terminal value, which accounts for the value of a business for the periods extending beyond the projection period, is also included. Together, the present value of the stream of cash flows and terminal value derive a total enterprise value of the subject company.<sup>9</sup>

17. The DCF calculation is based on the Disclosure Statement Projections for fiscal years 2024 – 2028 that reflect “Amyris 2.0.” To perform a DCF analysis, I determined Amyris’ projected unlevered free cash flows (“UFCF”) as set forth in the Disclosure Statement Projections as of January 1, 2024, and discount these projections back to August 9, 2023.

---

<sup>8</sup> IRS Revenue Ruling 59-60.

<sup>9</sup> I also considered the Comparable Publicly Traded Company (“CompCo”) and Comparable Transaction (“CompM&A”) methodologies. I ultimately rejected the CompCo method for a lack of meaningful financial metrics to conduct the analysis and rejected the CompM&A method for a lack of comparable transactions and a lack of meaningful financial metrics to conduct the analysis.

18. Since these projected cash flows are “unlevered,” or prior to the deduction of interest expense and debt principal repayments, the appropriate discount rate to apply to Amyris’ UFCF is its weighted average cost of capital (“WACC”). A company’s WACC represents its cost of financing and is calculated by multiplying its cost of equity by its percentage of capitalization that is equity, and adding to that the product of the after-tax cost of debt multiplied by the percentage of its capitalization that is debt.

19. The table below summarizes the present value of Amyris’ projected cash flows set forth in the Disclosure Statement Projections from FY2024 to FY2028, discounted at a WACC of 17.3%. As of August 9, 2023, Amyris’ go-forward enterprise value using the DCF method is \$105 million.<sup>10</sup>

---

<sup>10</sup> (1) The Disclosure Statement Projections reflect “Amyris 2.0”, which represents the reorganized company. These projections do not incorporate the restructuring costs incurred by the company from its bankruptcy filing to December 31, 2023.  
 (2) Projected a second stage step-down between the Disclosure Statement Projections and the normalized terminal year to gradually step-down the free cash flow growth rate of 31.2% in FY2028 to 3.0% in the terminal year.  
 (3) As of December 31, 2022, Amyris had a federal NOL balance of \$1.2 billion and a state NOL balance of \$291 million. I have assumed that Amyris will be able to carry this NOL forward post-emergence. Amyris is not projected to generate sufficient taxable income to utilize this NOL balance, therefore, I have assumed a tax rate of 0%. Source: Form 10-K, Amyris Inc., for the fiscal year ended December 31, 2022, p. 101.  
 (4) Calculated using the Gordon Growth Model. Terminal Value = (Normalized Terminal UFCF\*(1+PGR))/(WACC-PGR). I selected a perpetual growth rate (“PGR”) of 3.0% to reflect the midpoint between expected long-term inflation and nominal growth expectations.  
 (5) In preparation of this Declaration, I identified an error in my previous beta calculation for Amyris that was reflected in my expert report dated January 11, 2024. After correcting for this error, Amyris’ WACC decreased from 17.7% to 17.3%. This recalculation of the beta and the WACC resulted in an increase in the go-forward enterprise value of Amyris from \$97 million to \$105 million.

(\$ millions)	For the Fiscal Year					MSG's Extended Projections (2)					Terminal Value	
	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E		
Revenue	\$ 163	\$ 247	\$ 299	\$ 316	\$ 332							
Revenue Growth	90.4%	51.1%	21.4%	5.6%	5.1%							
EBITDA	\$ (66)	\$ (10)	\$ 28	\$ 42	\$ 51							
Less: Depreciation and Amortization	(19)	(22)	(24)	(25)	(28)							
EBIT	(85)	(32)	4	16	23							
Unlevered Cash Taxes @ 0.0% (3)	-	-	-	-	-							
Net Operating Profit After Tax	(85)	(32)	4	16	23							
Add: Depreciation and Amortization	19	22	24	25	28							
Less: Capital Expenditures	(42)	(24)	(27)	(24)	(19)							
Add/(less): Change in Net Working Capital	7	2	(2)	5	(0)							
Add: Ingredion Capital Call	13	5	6	5	4							
Less: Ingredion Profit Share	-	-	(3)	(5)	(5)							
Unlevered Free Cash Flows	\$ (88)	\$ (26)	\$ 2	\$ 23	\$ 30	\$ 38	\$ 47	\$ 55	\$ 62	\$ 66	\$ 66	
Terminal Value (4)											\$ 478	
Discount Period	0.89	1.89	2.89	3.89	4.89	5.89	6.89	7.89	8.89	9.89	9.89	
Discount Factor @ 17.3% WACC (5)	0.87	0.74	0.63	0.54	0.46	0.39	0.33	0.28	0.24	0.21	0.21	
Discounted Free Cash Flows	\$ (76)	\$ (20)	\$ 1	\$ 12	\$ 14	\$ 15	\$ 16	\$ 16	\$ 15	\$ 14	\$ 99	
PV of Cash Flows											6	
PV of Terminal Value											99	
<b>Concluded DCF Enterprise Value</b>	<b>\$ 105</b>											
			<b>FY27 - FY28 Growth</b>				<b>MSG's Step-Down Unlevered Free Cash Flow Growth</b>				<b>PGR</b>	
			31.2%				26.5%	21.8%	17.1%	12.4%	7.7%	3.0%

### Valuation of the Amyris IP

20. It is my opinion that, based on the Relief from Royalty (“RFR”) methodology (utilized in the valuation of IP Generating Ingredients Revenue) and the DCF methodology (utilized in the valuation of the IP Generating Licensing Revenue), the value of the Amyris IP is \$27.1 million as of August 9, 2023. It is my opinion that from August 9, 2023 to February 9, 2024, the value of the Amyris IP will not be materially different.

(\$ millions)	Valuation		
	Royalty Rate	Methodology Used	IP Value
<b>Ingredient IP</b>			
<b>IP Generating Ingredients Revenue</b>			
Ectoine	2.50%	RFR	\$ 1.3
HDF	2.50%	RFR	2.4
Squalene adjuvant	2.50%	RFR	2.2
Cholesterol (vaccine excipient)	1.75%	RFR	2.0
Cholesterol (cosmetic ingredient)	1.75%	RFR	1.4
<b>IP Generating Licensing Revenue</b>			
Licensing Revenue	N/A	DCF	17.9
<b>Previously Licensed IP Generating Ingredients Revenue</b>			
Various Ingredients	N/A	N/A	-
<b>Previously Licensed IP Not Generating Ingredients Revenue</b>			
Cannabinoids	N/A	N/A	-
<b>Total Value of Amyris IP</b>			<b>\$ 27.1</b>



21. Generally, there are three methodologies for valuing intellectual property, and specifically a patent: the income approach, the market approach and the cost approach.<sup>11</sup> I utilized the income approach as the appropriate methodology to value the Amyris IP. The income approach estimates the future cash flows generated from a specific piece of intellectual property. When valuing a patent using this methodology, there are several variables required to perform the analysis. These include, but are not limited to: (a) projected income stream associated with the product sales or licensing of the patent; (b) an estimated duration of the patent's useful life; (c) consideration of patent specific risk factors; and (d) a discount rate.

22. There are several methodologies used to value intellectual property utilizing the income approach. These include, but are not limited to the DCF and the RFR.<sup>12</sup>

23. The DCF method estimates the value of intellectual property by calculating the present value of the cash flows specifically attributable to the subject intellectual property, over the estimated life of the intellectual property. This methodology is very similar to how the enterprise value of a company would be determined using a DCF. The projected cash flows attributable to the subject intellectual property are forecasted for the useful life of the patent and discounted back at the company's discount rate, which assumes that the subject company's business risk is equivalent to the risk associated with the patent being valued. I utilized the DCF methodology, based on the Disclosure Statement Projections, as extended until December 31, 2033 consistent

---

<sup>11</sup> In this case, I rejected the market approach for valuing patents because, by definition, patents are unique and there are no patents that are directly comparable to the Amyris IP. I also rejected the cost approach because there is insufficient information to apply the historical cost, replication cost or replacement cost methodologies.

<sup>12</sup> I rejected the use of the Venture Capital Method in this case as it does not properly reflect the specific risks associated with a given patent.

with the DCF enterprise valuation of Amyris (utilizing a WACC of 17.3%, a PGR of 3% and Amyris' UFCF margin), to value the IP Generating Licensing Revenue at \$17.9 million.<sup>13</sup>

24. The RFR methodology is a standard framework used by financial professionals for valuing intangible assets. The RFR method estimates implied royalties over a projection period that the owner of the IP is "relieved" from paying due to owning the intangible asset, and then discounts those royalties by a discount rate back to the valuation date. In other words, the RFR method determines how much the subject company would have to pay to rent the IP from a third-party if it did not own it. While by definition a patent is unique, it is my opinion that the RFR method is a reasonable approach to value certain of the Amyris IP because comparable royalty rates are applied to Amyris-specific revenue. I utilized the RFR methodology to value the IP Generating Ingredients Revenue (Amyris' IP relating to ectoine (\$1.3 million), HDF (\$2.4 million), squalene adjuvant (\$2.2 million), cholesterol (vaccine excipient) (\$2.0 million), and cholesterol (cosmetic ingredient) (\$1.4 million)).

25. Previously Licensed IP Generating Ingredients Revenue includes licenses relating to technology that has been licensed to third-parties pursuant to research and collaboration agreements and/or that have been granted in perpetuity to third-parties for the fields of use that are contemplated in the Disclosure Statement Projections (Bisabolol, GAA, Hemisqualane, Manool, Pachouli, RebM, Retinol, Sandalwood, Sclareol, Squalane and Vanillin). It is my opinion that, because the Previously Licensed IP Generating Ingredients Revenue have been perpetually licensed to third-parties and/or the Disclosure Statement Projections do not contain projected revenue from such research and collaboration agreements, it has no value to Amyris.

---

<sup>13</sup> Due to the change in the WACC (from 17.7% in my expert report dated January 11, 2024 to 17.3% utilized here), the value of the IP Generating Licensing Revenue increased from \$16.8 million to \$17.9 million.

**Valuation of the Consumer Brands IP**

26. It is my opinion that, as of August 9, 2023, the value of the Consumer Brands IP is \$9.4 million, as set forth in the below chart. It is my opinion that from August 9, 2023 to February 9, 2024, the value of the Consumer Brands IP will not be materially different.

(\$ millions) Brand	Concluded Value
Biossance	\$ 6.6
JVN	0.5
Rose Inc	0.6
Pipette	0.6
MenoLabs	0.8
Stripes	0.2
4U by Tia	0.2
<b>Total Consumer Brand Value</b>	<b>\$ 9.4</b>

27. To determine the value of the Consumer Brands IP, I first reviewed and analyzed the purchase price paid by third-parties to buy each consumer brand business. Next, utilizing comparable transactions I identified through the Markables database,<sup>14</sup> I determined the proportion of the purchase price that was attributable to the brand IP.

28. According to the *Motion for an Order Approving Bid Procedures* filed on September 18, 2023, at that time there were already 300 potential buyers, 200 of whom were active, 85 of whom had signed non-disclosure agreements to be given access to the data room, and more than a dozen had submitted non-binding indications of interest.<sup>15</sup> The large number of parties that expressed interest in buying Amyris' consumer brands business supports the notion that the

<sup>14</sup> Per its website, Markables database is a 24/7 web-based data vendor which caters to the needs of valuation professionals all over the world. For more information, see <https://www.markables.net/>.

<sup>15</sup> *Motion for an Order Approving Bid Procedures*, filed September 18, 2023, p. 7, ¶ 15. [Docket No. 316].

purchase price of the various consumer brands business was based on an arm's length transaction and therefore is representative of the fair market value of the consumer brands businesses acquired.

29. As a test of reasonableness of my concluded value for the Consumer Brands IP, I compared the difference between the enterprise value/purchase price and the brand value for each brand to the book value of the assets acquired in each asset purchase agreement. In each case, inventory was acquired by the purchaser and in 3 of the 7 transactions (Biossance, Rose Inc. and 4U by Tia), accounts receivable was acquired. Various other assets including marketing materials, accounting records, contracts, warranties, permits, and office equipment were also acquired. Conservatively, I placed no value on these other assets acquired.

30. In total, my valuation of the Consumer Brands IP implies that the other assets acquired were acquired at approximately one-third of their book values. This confirms the reasonableness of my brand value.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct.

Dated: January 22, 2024

/s/ Bradley M. Orelowitz

Bradley M. Orelowitz

Managing Director

Back Bay Management Corporation and its division,  
The Michel-Shaked Group

---

# **Exhibit 1**

---

# BRADLEY M. ORELOWITZ, CPA

Phone: (617) 895-5005  
borelowitz@michel-shaked.com

2 Park Plaza, Suite 500  
Boston, MA 02116

## EDUCATION

---

<b>Boston University Graduate School of Management</b> , Boston, MA	January 2000
Master of Business Administration (MBA), High Honors Concentration in Finance Beta Gamma Sigma Honors Society Vice President Student-Alumni Network.	
<b>University of South Africa</b> , Pretoria, South Africa	
Honors Bachelor of Accounting Science	1993
Bachelor of Commerce, Accounting	1992

## PROFESSIONAL DESIGNATIONS

---

<b>Massachusetts Board of Public Accountancy</b> Certified Public Accountant (CPA)	2000 - Present
---	----------------

Previously registered with the South African Institute of Chartered Accountants and the South African Public Accountants' and Auditors' Board as a Chartered Accountant.

## PROFESSIONAL EXPERIENCE

---

<b>The Michel-Shaked Group</b> , Boston, MA <i>Managing Director, Expert</i>	1999 - Present
<b>PensionLitigationData.com</b> , Boston, MA <i>Managing Director, Co-founder</i>	2005 - 2011
<b>Forma Viva Fine Jewellery</b> , Johannesburg, South Africa <i>Chief Financial Officer, Owner</i>	1996 - 1998
<b>EHD Components</b> , Johannesburg, South Africa <i>Consultant</i>	1995 - 1996
<b>Papilsky Hurwitz Public Accountants</b> , Johannesburg, South Africa <i>Audit Manager</i>	1989 - 1995

## **SELECT PRACTICE AREAS**

---

- Valuation
- Bankruptcy
- Taxation
- Accounting
- Damages
- Securities
- Capital Markets
- Financial Modeling
- Corporate Advisory
- Pension and Employment
- Seminars

## **SELECT INDUSTRIES**

---

- Automotive
- B2B E-Commerce
- Banking
- Cable
- Chemicals
- Construction
- Custodial Services
- Drug Distribution
- Education
- Electrical
- Energy
- Financial Services
- Food and Beverage
- Health Care
- Hotels and Casinos
- Industrial
- Insurance
- Leasing
- Leisure
- Manufacturing
- Media
- Medical Devices
- Mining
- Mortgage Servicing
- Oil and Gas
- Payroll Processing
- Pharmaceuticals
- Private Equity
- Professional Sports
- Real Estate
- Retail
- Software
- Solid Waste
- Steel
- Subscription Services
- Technology
- Telecommunications
- Textiles
- Tire & Rubber
- Tobacco

## **PUBLICATIONS**

---

- (Book) Primrose, S. (Editor), Best of ABI 2022: The Year in Business Bankruptcy, American Bankruptcy Institute, 2022 (Select chapter).
- (Book) Shaked, I. and R. Reilly, A Practical Guide to Bankruptcy Valuation, 2nd edition, American Bankruptcy Institute, 2017 (Select chapters).
- (Book) Shaked, I. and R. Reilly, A Practical Guide to Bankruptcy Valuation, American Bankruptcy Institute, 2013 (Select chapters).

“Demystifying a Company’s Systematic Risk.” (with I. Shaked), American Bankruptcy Institute Journal, February 2022.

“The Cost of Capital Dilemma: Valuation During Abnormal Market Conditions.” (with I. Shaked and P. Dionne), American Bankruptcy Institute Journal, April 2021.

“The Airline Industry and Covid-19: Saving for a Rainy Day.” (with I. Shaked), American Bankruptcy Institute Journal, May 2020.

“10 Common Causes of Distress.” (with I. Shaked), American Bankruptcy Institute Journal, July 2018.

“Key Valuation Issues in Distressed Investing.” (with I. Shaked), Journal of Corporate Renewal, January/February 2018.

“Understanding Retail Bankruptcy.” (with I. Shaked), American Bankruptcy Institute Journal, November 2017.

“Judging Fraud: The Case of Relying on Wrong Information.” (with I. Shaked and E. Weisfelner), American Bankruptcy Institute Journal, August 2016.

“Contingent Liabilities: GAAP vs. Valuation Perspective.” (with I. Shaked). American Bankruptcy Institute Journal, August 2015.

“Role of Uncertainty in Determining a Distressed Company’s Fate.” (with I. Shaked). American Bankruptcy Institute Journal, October 2014.

“Muni Bonds, Pension Liabilities and Investment Due Diligence.” (with S. Mangiero and I. Shaked). American Bankruptcy Institute Journal, July 2014.

“FMV and Going-Concern Value Compared: An Expert’s Opinion.” (with I. Shaked). American Bankruptcy Institute Journal, April 2014.

“Cornerstone of Financial Decision-Making: Credible Projections.” (with I. Shaked). American Bankruptcy Institute Journal, October 2013.

“The Valuation of NOLs in a Bankruptcy Reorganization.” (with I. Shaked). American Bankruptcy Institute Journal, July 2013.

“Quantifying the Impact of Fraud: Application of the Guideline Publicly Traded Company Approach.” (with I. Shaked). American Bankruptcy Institute Journal, April 2013.

“Case Studies in Corporate Bankruptcy Valuation.” (with I. Shaked). American Bankruptcy Institute Journal, August 2012.



“Bankruptcy Valuation Hearings: As Highly Contested as Ever.” (with I. Shaked). American Bankruptcy Institute Journal, November 2011.

“Comparable Company Valuation Methodology: Details Often Overlooked.” (with M. Marcus and I. Shaked). American Bankruptcy Institute Journal, April 2010.

“ERISA Litigation Study.” (with S. Mangiero, E. Preble, I. Shaked and J. Sheffield). Investment Governance, Inc. and The Michel-Shaked Group. April 2009.

“The Mirant Valuation Saga: Epic Battle of Experts.” (with A. Michel and I. Shaked). American Bankruptcy Institute Journal, December 2004/January 2005.

## **PRESENTATIONS**

---

“Welcome to the Jungle: Expert Witness Preparation and Testimony.” 97<sup>th</sup> Annual Conference of the National Conference of Bankruptcy Judges (NCBJ), J.W. Marriott, Austin, TX, October 13, 2023.

“Enterprise Valuation Today: “It Ain't What It Used to Be” Annual Spring Meeting 2023, The American Bankruptcy Institute (ABI), J.W. Marriott, Washington, DC, April 22, 2023.

“The Pandemic Era: Did Corporate Valuation Change?” Valuation Conference (Valcon 2022), The American Bankruptcy Institute (ABI) and Association of Insolvency & Restructuring Advisors (AIRA), Four Seasons, Las Vegas, Nevada, May 12, 2022.

“Valuation Discounts Under Siege: The Case Against Irrationality” (with I. Shaked), LandVest, Boston, MA, November 14, 2016.

“Looking Behind the Numbers: Understanding a Company’s True Financial Health” (with I. Shaked), Brown Rudnick, Boston, MA, April 30, 2015

“Cross-Examining a Financial Expert in Valuation Cases: The Key Issues” (with I. Shaked), Sullivan & Worcester, Boston, MA, November 5, 2013.

## **AWARDS AND HONORS**

---

“Demystifying a Company’s Systematic Risk.” (with I. Shaked), American Bankruptcy Institute Journal, February 2022, selected for inclusion in Best of ABI 2022: The Year in Business Bankruptcy

“Muni Bonds, Pension Liabilities and Investment Due Diligence.” (with S. Mangiero and I. Shaked)  
Top Ten List-Social Science Research Network (SSRN), 2014.

Beta Gamma Sigma Honors Society

Winner: 1999 Annual Students for Responsible Business Case Competition

**MEMBERSHIPS**

---

American Bankruptcy Institute (ABI)

American Institute of Certified Public Accountants (AICPA)

**TESTIMONIES WITHIN PAST FOUR YEARS**

---

Tailored Brands, Inc., et al., Debtors

United States Bankruptcy Court, Southern District of Texas, Houston Division, Chapter 11

Case No. 20-33900 (MI)

Report Submission and Deposition Testimony

2020

---

## **Exhibit 2**

---

# Overview of Amyris IP

---

## Valuation of Amyris IP

- **IP Generating Ingredients Revenue**: IP that Amyris owns where it generates revenue through the production and sale of certain ingredients.
  - This includes the IP relating to the following new ingredients: ectoine, HDF, squalene adjuvant, cholesterol (vaccine excipient), and cholesterol (cosmetic ingredient). This IP is included in my valuation of the Amyris IP.
- **IP Generating Licensing Revenue**: Licensing fees and royalty streams from new molecules.
  - This includes the IP that Amyris owns or will develop in the future, for example, alternative uses for Amyris' Farnesene IP. This IP is included in my valuation of the Amyris IP.
- **Previously Licensed IP Generating Ingredients Revenue**: Licenses to the technology that have been granted in perpetuity for the fields of use that are contemplated in the Disclosure Statement Projections.
  - I have been advised that this includes the IP relating to the following ingredients: bisabolol, GAA, hemisqualane, manool, pachouli, RebM, retinol, sandalwood, sclareol, squalane, and vanillin. As this IP has been perpetually licensed to third-parties, it has no value to Amyris, and thus, I have assigned no value in my valuation.
- **Previously Licensed IP Not Generating Ingredients Revenue**
  - I have been advised that the Cannabinoid IP has been licensed to Lavvan, Inc. Furthermore, the Cannabinoid IP is not profitable and is not projected to generate any revenue in the Disclosure Statement Projections. Thus, the Cannabinoid IP has no value.
- **Brand Names and Trademarks**:
  - As Amyris generates value through the use of its patents in manufacturing ingredients made with synthetic biology, it does not rely on its brand names and trademarks to create value. Therefore, the value of its brand name and trademarks is de minimis.

# Valuation of the Amyris IP

## Concluded Value

- Based on the Relief from Royalty (“RFR”) methodology and the DCF methodology, the value of the Amyris IP is \$27.1 million<sup>1</sup> as of August 9, 2023. It is my opinion that from August 9, 2023 to February 9, 2024 the value of the Amyris IP will not be materially different.

Ingredient IP	Valuation		
	Royalty Rate	Methodology Used	IP Value
<b>(\$ millions)</b>			
<b>IP Generating Ingredients Revenue</b>			
Ectoine	2.50%	RFR	\$ 1.3
HDF	2.50%	RFR	2.4
Squalene adjuvant	2.50%	RFR	2.2
Cholesterol (vaccine excipient)	1.75%	RFR	2.0
Cholesterol (cosmetic ingredient)	1.75%	RFR	1.4
<b>IP Generating Licensing Revenue</b>			
Licensing Revenue	N/A	DCF	17.9
<b>Previously Licensed IP Generating Ingredients Revenue</b>			
Various Ingredients	N/A	N/A	-
<b>Previously Licensed IP Not Generating Ingredients Revenue</b>			
Cannabinoids	N/A	N/A	-
<b>Total Value of Amyris IP</b>			<b>\$ 27.1</b>

- As Previously Licensed IP Generating Ingredients Revenue has been perpetually licensed to third-parties, it has no value to Amyris.
- The Cannabinoid IP has no value for the following reasons:
  - I have been advised by counsel that the Cannabinoid IP has been licensed to Lavvan, Inc.
  - In a declaration dated December 6, 2023, the interim CEO and CFO of Amyris, Han Kieftenbeld, stated that from December 2020 through December 2023, Amyris’ cost of producing cannabinoids was “significantly higher than revenues generated from the CBG sales” and that “Amyris made no profits on the sale of CBG.”<sup>2</sup>
  - The Disclosure Statement Projections do not contain projected revenue for Cannabinoid IP.

(1) In my review of this report, I identified an error in my previous beta calculation for Amyris. After correcting for this error, Amyris’ WACC decreases from 17.7% to 17.3% and the total value of Amyris IP increases from \$25.8 million to \$27.1 million.

(2) Declaration of Han Kieftenbeld in Support of Debtors’ Objection to Claim Nos. 663 and 666 Filed by Lavvan, Inc., filed on December 6, 2023, p. 2 (Docket 839).

---

## **Exhibit 3**

---



**Patent Portfolio (owned, co-owned, or licensed by Amyris)  
as of: March 5, 2019**

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM- 400	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	US 11/753,586	US 7,854,774	2010-12-21	2028-03-28
AM- 500	Production of Isoprenoids	US 11/754,235	US 7,659,097	2010-02-09	2027-12-24
AM- 500 C2	Production of Isoprenoids	US 13/848,045	US 9,200,296	2015-12-01	2028-01-11
AM- 500 C3	Production of Isoprenoids	US 14/921,905	US 10,106,822	2018-10-23	2027-05-25
AM- 500 AU	Production of Isoprenoids	AU 2007267033	AU 2007267033	2012-09-06	2027-05-25
AM- 500 AU D1	Production of Isoprenoids	AU 2012202630	AU 2012202630	2014-05-01	2027-05-25
AM- 500 BR	Production of Isoprenoids	BR PI0713105-4	BR PI0713105-4	2019-01-15	2029-01-15
AM- 500 CA	Production of Isoprenoids	CA 2,651,747	CA 2,651,747	2017-10-24	
AM- 500 CN	Production of Isoprenoids	CN 200780019353.4	CN ZL200780019353.4	2013-03-27	2027-05-25
AM- 500 EP D1	Production of Isoprenoids	EP 15200471.9			
AM- 500 EP-CH	Production of Isoprenoids	EP 07797800.5	EP 2024504	2016-02-24	2027-05-25
AM- 500 EP-DE	Production of Isoprenoids	EP 07797800.5	EP 2024504	2016-02-24	2027-05-25
AM- 500 EP-DK	Production of Isoprenoids	EP 07797800.5	EP 2024504	2016-02-24	2027-05-25
AM- 500 EP-FR	Production of Isoprenoids	EP 07797800.5	EP 2024504	2016-02-24	2027-05-25
AM- 500 EP-GB	Production of Isoprenoids	EP 07797800.5	EP 2024504	2016-02-24	2027-05-25
AM- 500 EP-NL	Production of Isoprenoids	EP 07797800.5	EP 2024504	2016-02-24	2027-05-25
AM- 500 IN	Production of Isoprenoids	IN 9907/DELNP/2008	IN 268805	2015-09-18	2027-05-25
AM- 500 KR	Production of Isoprenoids	KR 10-2008-7029580	KR 1417146	2014-06-30	2027-05-25
AM- 500 MX	Production of Isoprenoids	MX/a/2008/014909	MX 284139	2011-02-18	2027-05-25
AM- 500 MY	Production of Isoprenoids	MY PI20084571	MY 146612-A	2012-09-14	2027-05-25
AM- 500 SG	Production of Isoprenoids	SG 200808367-7	SG 147734	2011-08-31	2027-05-25
AM- 500 VN	Production of Isoprenoids	VN 1-2008-02948	VN 9835	2011-11-16	2027-05-25

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM- 500 VN D1	Production of Isoprenoids	VN 1-2011-02981			
AM- 500 ZA	Production of Isoprenoids	ZA 2008/09621	ZA 2001/09621	2011-04-28	2027-05-25
AM- 700	Apparatus for Making a Bio-Organic Compound	US 11/807,048	US 9,765,363	2017-09-19	2028-12-15
AM- 700 AU	Apparatus for Making a Bio-Organic Compound	AU 2007267913	AU 2007267913	2013-05-09	2027-05-25
AM- 700 BR	Apparatus for Making a Bio-Organic Compound	BR PI0712508-9	BR PI0712508-9	2018-04-10	2028-04-10
AM- 700 CA	Apparatus for Making a Bio-Organic Compound	CA 2,652,801	CA 2,652,801	2018-05-22	
AM- 700 CN	Apparatus for Making a Bio-Organic Compound	CN 200780028412.4			
AM- 700 EP-DE	Apparatus for Making a Bio-Organic Compound	EP 07777278.8	EP 2021486	2014-10-29	2027-05-25
AM- 700 EP-DK	Apparatus for Making a Bio-Organic Compound	EP 07777278.8	EP 2021486	2014-10-29	2027-05-25
AM- 700 EP-ES	Apparatus for Making a Bio-Organic Compound	EP 07777278.8	EP 2021486	2014-10-29	2027-05-25
AM- 700 EP-FR	Apparatus for Making a Bio-Organic Compound	EP 07777278.8	EP 2021486	2014-10-29	2027-05-25
AM- 700 EP-GB	Apparatus for Making a Bio-Organic Compound	EP 07777278.8	EP 2021486	2014-10-29	2027-05-25
AM- 700 EP-IT	Apparatus for Making a Bio-Organic Compound	EP 07777278.8	IT 502015902326819	2014-10-29	2027-05-25
AM- 700 HK	Apparatus for Making a Bio-Organic Compound	HK 09102854.2	HK 1122595	2015-02-18	2027-05-25
AM- 700 ID	Apparatus for Making a Bio-Organic Compound	ID W00200803809	IDP000035924	2014-04-30	2027-05-25
AM- 700 JP D3	Apparatus for Making a Bio-Organic Compound	JP 2015-157021			
AM- 700 KR	Apparatus for Making a Bio-Organic Compound	KR 10-2008-7031413	KR 10-1420889	2014-07-11	2027-05-25
AM- 700 MX	Apparatus for Making a Bio-Organic Compound	MX/a/2008/014970	MX 293430	2011-12-09	2027-05-25
AM- 700 MY	Apparatus for Making a Bio-Organic Compound	MY PI20084768	MY 163029-A	2017-07-31	
AM- 700 SG	Apparatus for Making a Bio-Organic Compound	SG 200808725-6	SG 148288	2011-06-30	2027-05-25
AM- 700 VN	Apparatus for Making a Bio-Organic Compound	VN 1-2008-03155	VN 15060	2016-01-11	2027-05-25
AM- 700 ZA	Apparatus for Making a Bio-Organic Compound	ZA 2008/09957	ZA 2008/09957	2010-08-10	2027-05-25
AM- 800	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	US 11/869,673	US 7,399,323	2008-07-15	2027-10-09



Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM- 800 AU	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	AU 2007308137	AU 2007308137	2011-07-14	2027-10-10
AM- 800 BR	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	BR PI0719659-8			
AM- 800 CA	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	CA 2,665,198	CA 2,665,198	2016-06-28	2027-10-10
AM- 800 CN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	CN 200780045575.3	CN ZL200780045575.3	2015-08-26	2027-10-10
AM- 800 CO	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	CO 09040600	CO 2725	2013-01-28	2027-10-10
AM- 800 EP-DE	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	EP 07839526.6	DE 60 2017 049 262.0	2016-12-21	2027-10-10
AM- 800 EP-FR	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	EP 07839526.6	EP 2084249	2016-12-21	2027-10-10
AM- 800 EP-GB	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	EP 07839526.6	EP 2084249	2016-12-21	2027-10-10
AM- 800 GT	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	GT A-2009-0078			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM- 800 HK	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	HK 20090107399	HK 1127510	2018-01-05	2027-10-10
AM- 800 HN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	HN 2009-000616	HN 5123, Folio 75, vol XII	2011-11-29	2027-10-10
AM- 800 IN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	IN 2382/CHENP/2009	IN 288724	2017-10-30	2027-10-10
AM- 800 JP	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	JP 2009-532447	JP 5528110	2014-04-25	2027-10-10
AM- 800 KR	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	KR 10-2009-7009520	KR 10-1543777	2015-08-05	2027-10-10
AM- 800 MX	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	MX/a/2009/003715	MX 285041	2011-03-25	2027-10-10
AM- 800 MY	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	MY PI20091396	MY 145076-A	2011-12-15	2027-10-10
AM- 800 MZ	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	MZ 152/2009	MZ 152/2009	2012-12-27	2027-10-10
AM- 800 NI	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	NI 2009-000047	NI 2068 RPI	2011-10-27	2027-10-10

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM- 800 SG	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	SG 200902252-6	SG 151535	2012-07-31	2027-10-10
AM- 800 SV	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	SV 2009007776	SV E-3208-2009	2016-04-15	2027-10-10
AM- 800 TT	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	TT/A/2009/00087	TT/P/2015/00047	2015-06-17	2027-10-10
AM- 800 VN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	VN 1-2009-00933	VN 11469	2013-06-10	2027-10-10
AM- 800 ZA	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	ZA 2009/02205	ZA 2009/02205	2010-09-29	2027-10-10
AM- 801	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	US 11/973,901	US 7,846,222	2010-12-07	2029-04-12
AM- 900	Jet Fuel Compositions and Methods of Making and Using the Same	US 11/986,484	US 7,942,940	2011-05-17	2030-03-16
AM- 900 AU	Jet Fuel Compositions and Methods of Making and Using the Same	AU 2007353411	AU 2007353411	2011-12-01	2027-11-20
AM- 900 CA	Jet Fuel Compositions and Methods of Making and Using the Same	CA 2,670,307	CA 2,670,307	2013-06-25	2027-11-20
AM- 900 CN	Jet Fuel Compositions and Methods of Making and Using the Same	CN 200780050238.3	CN ZL200780050238.3	2016-01-20	2027-11-20
AM- 900 ZA	Jet Fuel Compositions and Methods of Making and Using the Same	ZA 2009/03365	ZA 2009/03365	2010-08-25	2027-11-20
AM-1200	Jet Fuel Compositions and Methods for Making and Using the Same	US 11/986,485	US 7,935,156	2011-05-03	2030-02-17

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-1200 AU	Jet Fuel Compositions and Methods for Making and Using the Same	AU 2007352386	AU 2007352386	2012-01-25	2027-11-20
AM-1200 CN	Jet Fuel Compositions and Methods for Making and Using the Same	CN 200780050177.0	CN ZL200780050177.0	2013-04-17	2027-11-20
AM-1200 ZA	Jet Fuel Compositions and Methods for Making and Using the Same	ZA 2009/03366	ZA 2009/03366	2010-10-27	2027-11-20
AM-1400	Production of Isoprenoids	US 12/234,589			
AM-1400 AU	Production of Isoprenoids	AU 2008305655	AU 2008305655	2014-02-13	2028-09-19
AM-1400 BR	Production of Isoprenoids	BR PI0816951-9			
AM-1400 CA	Production of Isoprenoids	CA 2,700,211			
AM-1400 EP-CH	Production of Isoprenoids	EP 08832899.2	EP 2217711	2015-08-26	2028-09-19
AM-1400 EP-DE	Production of Isoprenoids	EP 08832899.2	EP 2217711	2015-08-26	2028-09-19
AM-1400 EP-DK	Production of Isoprenoids	EP 08832899.2	EP 2217711	2015-08-26	2028-09-19
AM-1400 EP-FR	Production of Isoprenoids	EP 08832899.2	EP 2217711	2015-08-26	2028-09-19
AM-1400 EP-GB	Production of Isoprenoids	EP 08832899.2	EP 2217711	2015-08-26	2028-09-19
AM-1400 EP-IE	Production of Isoprenoids	EP 08832899.2	EP 2217711	2015-08-26	2028-09-19
AM-1400 EP-NL	Production of Isoprenoids	EP 08832899.2	EP 2217711	2015-08-26	2028-09-19
AM-1400 IN	Production of Isoprenoids	IN 2183/CHENP/2010	IN 281883	2017-03-28	2028-09-19
AM-1400 MX	Production of Isoprenoids	MX/a/2010/002990	MX 302107	2012-08-08	2028-09-19
AM-1400 ZA	Production of Isoprenoids	ZA 2010/02000	ZA 2010/02000	2011-05-25	2028-09-19
AM-1700	Methods of Monitoring Metabolic Pathways	US 12/361,478	US 8,450,080	2013-05-28	2031-07-22
AM-1900	Jet Fuel Compositions and Methods of Making and Using the Same	US 12/431,769	US 7,671,245	2010-03-02	2029-04-29
AM-1900 AU	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	AU 2009243064	AU 2009243064	2013-12-19	2029-04-29
AM-1900 BR	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	BR PI0911865-9	BR PI0911865-9	2017-08-22	2029-04-29

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-1900 EP-DE	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	EP 09739748.3	EP 2288675	2013-06-12	2029-04-29
AM-1900 EP-FR	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	EP 09739748.3	EP 2288675	2013-06-12	2029-04-29
AM-1900 EP-GB	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	EP 09739748.3	EP 2288675	2013-06-12	2029-04-29
AM-1900 ZA	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	ZA 2010/07910	ZA 2010/07910	2012-02-29	2029-04-29
AM-1901	Jet Fuel Compositions and Methods of Making and Using the Same	US 12/432,733	US 8,106,247	2012-01-31	2030-06-12
AM-2100	Farnesene Interpolymers	US 12/552,282	US 8,217,128	2012-07-10	2029-07-23
AM-2100 AU	Farnesene Interpolymers	AU 2009288676	AU 2009288676	2013-08-22	2029-09-03
AM-2100 BR	Farnesene Interpolymers	BR PI0918225-0			
AM-2100 CA	Farnesene Interpolymers	CA 2,735,257	CA 2,735,257	2017-02-28	2029-09-03
AM-2100 CN	Farnesene Interpolymers	CN 200980138182.6	CN ZL200980138182.6	2012-11-21	2029-09-03
AM-2100 EP-CH	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-DE	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-ES	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-FR	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-GB	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-IE	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-IT	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-NL	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 EP-SE	Farnesene Interpolymers	EP 09789249.1	EP 2328943	2012-01-25	2029-09-03
AM-2100 IN	Farnesene Interpolymers	IN 2210/CHENP/2011	IN 299016	2018-07-20	
AM-2100 JP	Farnesene Interpolymers	JP 2011-526040	JP 5667679	2014-12-19	2029-09-03
AM-2100 KR	Farnesene Interpolymers	KR 10-2011-7007803	KR 10-1626845	2016-05-27	2029-09-03
AM-2100 MX	Farnesene Interpolymers	MX/a/2011/002438	MX 294796	2012-01-16	2029-09-03
AM-2100 SG	Farnesene Interpolymers	SG 201101526-0	SG 169492	2013-09-13	2029-09-03
AM-2100 TW	Farnesene Interpolymers	TW 098129823	TW I393742	2013-04-21	2029-09-03
AM-2100 ZA	Farnesene Interpolymers	ZA 2011/01512	ZA 2011/01512	2012-04-25	2029-09-03
AM-2101	Polyfarnesenes by Metal-Catalyzed Insertion Polymerizations	US 13/365,250	US 8,334,353	2012-12-18	2029-07-23

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-2102	Polyfarnesenes by Metal-Catalyzed Insertion Polymerizations	US 13/480,490	US 8,889,808	2014-11-18	2029-07-23
AM-2110	Polyfarnesenes	US 13/409,129	US 8,592,543	2013-11-26	2029-07-23
AM-2200	Jet Fuel Compositions	US 12/393,024	US 7,589,243	2009-09-15	2029-02-25
AM-2200 AU	Jet Fuel Compositions	AU 2009292619	AU 2009292619		2029-09-16
AM-2200 BR	Jet Fuel Compositions	BR PI0918638-7	BR PI0918638-7	2018-07-03	2029-09-16
AM-2200 CA	Jet Fuel Compositions	CA 2,736,759	CA 2,736,759	2017-04-11	2029-09-16
AM-2200 CN	Jet Fuel Compositions	CN 200980144962.1	CN ZL200980144962.1	2013-09-04	2029-09-16
AM-2200 EP-DE	Jet Fuel Compositions	EP 09789314.3	EP 2342310	2013-01-09	2029-09-16
AM-2200 EP-ES	Jet Fuel Compositions	EP 09789314.3	EP 2342310	2013-01-09	2029-09-16
AM-2200 EP-FR	Jet Fuel Compositions	EP 09789314.3	EP 2342310	2013-01-09	2029-09-16
AM-2200 EP-GB	Jet Fuel Compositions	EP 09789314.3	EP 2342310	2013-01-09	2029-09-16
AM-2200 EP-IT	Jet Fuel Compositions	EP 09789314.3	EP 2342310	2013-01-09	2029-09-16
AM-2200 JP	Jet Fuel Compositions	JP 2011-527811	JP 5416777	2013-11-22	2029-09-16
AM-2200 KR	Jet Fuel Compositions	KR 10-2011-7008675	KR 10-1562965	2015-10-19	2029-09-16
AM-2200 MX	Jet Fuel Compositions	MX/a/2011/002831	MX 315828	2013-11-28	2029-09-16
AM-2200 SG	Jet Fuel Compositions	SG 201101827-2	SG 169658	2013-09-30	2029-09-16
AM-2200 ZA	Jet Fuel Compositions	ZA 2011/01853	ZA 2011/01853	2012-05-30	2029-09-16
AM-2300	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	US 12/409,437	US 7,592,295	2009-09-22	2029-03-23
AM-2310	Lubricant Compositions	US 12/577,093	US 7,691,792	2010-04-06	2029-10-09
AM-2310 BR	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	BR PI0919697-8	BR PI0919697-8	2018-02-06	2029-10-09
AM-2310 EP-DE	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	EP 09740208.5	EP 2349956	2016-09-14	2029-10-09
AM-2310 EP-FR	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	EP 09740208.5	EP 2349956	2016-09-14	2029-10-09
AM-2310 EP-GB	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	EP 09740208.5	EP 2349956	2016-09-14	2029-10-09
AM-2310 US	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	US 13/123,514	US 8,669,403	2014-03-11	2029-03-23
AM-2400	Compositions and Methods for the Rapid Assembly of Polynucleotides	US 12/622,401	US 8,221,982	2012-07-17	2030-12-15
AM-2400 C1	Compositions and Methods for the Rapid Assembly of Polynucleotides	US 12/684,874	US 8,110,360	2012-02-07	2030-06-25
AM-2400 C2	Compositions and Methods for the Rapid Assembly of Polynucleotides	US 13/430,322	US 8,546,136	2013-10-01	2029-11-19
AM-2400 AU	Compositions and Methods for the Rapid	AU 2009316660	AU 2009316660	2015-05-14	2029-11-19

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
	Assembly of Polynucleotides				
AM-2400 BR	Compositions and Methods for the Rapid Assembly of Polynucleotides	BR PI0922187-5			
AM-2400 CA	Compositions and Methods for the Rapid Assembly of Polynucleotides	CA 2,744,153			
AM-2400 CN	Compositions and Methods for the Rapid Assembly of Polynucleotides	CN 200980154897.0	CN ZL200980154897.0	2014-05-07	2029-11-19
AM-2400 EP-CH	Compositions and Methods for the Rapid Assembly of Polynucleotides	EP 09764127.8	EP 2358875	2015-08-12	2029-11-19
AM-2400 EP-DE	Compositions and Methods for the Rapid Assembly of Polynucleotides	EP 09764127.8	EP 2358875	2015-08-12	2029-11-19
AM-2400 EP-FR	Compositions and Methods for the Rapid Assembly of Polynucleotides	EP 09764127.8	EP 2358875	2015-08-12	2029-11-19
AM-2400 EP-GB	Compositions and Methods for the Rapid Assembly of Polynucleotides	EP 09764127.8	EP 2358875	2015-08-12	2029-11-19
AM-2400 EP-IE	Compositions and Methods for the Rapid Assembly of Polynucleotides	EP 09764127.8	EP 2358875	2015-08-12	2029-11-19
AM-2400 EP-NL	Compositions and Methods for the Rapid Assembly of Polynucleotides	EP 09764127.8	EP 2358875	2015-08-12	2029-11-19
AM-2400 IN	Compositions and Methods for the Rapid Assembly of Polynucleotides	IN 4129/CHENP/2011			
AM-2400 KR	Compositions and Methods for the Rapid Assembly of Polynucleotides	KR 10-2011-7014144	KR 10-1794298	2017-10-31	2029-11-19
AM-2400 MX	Compositions and Methods for the Rapid Assembly of Polynucleotides	MX/a/2011/005195	MX 307547	2013-02-27	2029-11-19
AM-2400 MX D1	Compositions and Methods for the Assembly of Polynucleotides	MX/a/2012/011877	MX 317111	2014-01-14	2029-11-19

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-2400 SG	Compositions and Methods for the Rapid Assembly of Polynucleotides	SG 201103627-4	SG 171760	2012-09-14	2029-11-19
AM-2400 ZA	Compositions and Methods for the Rapid Assembly of Polynucleotides	ZA 2011/03637	ZA 2011/03637	2013-08-29	2029-11-19
AM-2500	Microbial Derived Isoprene and Methods for Making the Same	US 12/659,216	US 8,324,442	2012-12-04	2031-06-15
AM-2500 D1	Microbial Derived Isoprene and Methods for Making the Same	US 13/629,623	US 8,492,605	2013-07-23	2030-03-01
AM-2500 D2	Microbial Derived Isoprene and Methods for Making the Same	US 13/887,381	US 9,233,894	2016-01-12	2030-05-29
AM-2500 D3	Microbial Derived Isoprene and Methods for Making the Same	US 14/956,402	US 9,885,061	2018-02-06	2030-06-28
AM-2500 D3C1	Microbial Derived Isoprene and Methods for Making the Same	US 15/851,715	US 10,125,376	2018-11-13	2030-03-01
AM-2600	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	US 12/753,413	US 8,519,204	2013-08-27	2031-12-31
AM-2600 C1	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	US 15/458,907	US 10,183,901	2019-01-22	2030-07-31
AM-2600 C2	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	US 156/228,567			
AM-2600 D1	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	US 13/951,137	US 9,611,189	2017-04-04	2031-11-29
AM-2600 AU	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	AU 2010232469	AU 2010232469	2014-01-02	2030-04-02
AM-2600 BR	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	BR PI1015250-4			
AM-2600 BR D1	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	BR 12 2018 010309 4			
AM-2600 BR D2	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	BR 12 2018 010313 2			



Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-2600 CA	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	CA 2,757,000	CA 2,757,000	2018-02-13	2030-04-02
AM-2600 CA D1	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	CA 2,989,631			
AM-2600 CN	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	CN 201080024164.8	CN ZL201080024164.8	2015-04-29	2030-04-02
AM-2600 EP-BG	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 EP-CH	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 EP-DE	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 EP-DK	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 EP-ES	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	ES 2638774 T3	2017-06-07	2030-04-02
AM-2600 EP-FR	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 EP-GB	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 EP-NL	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 EP-PT	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	EP 10712281.4	EP 2414311	2017-06-07	2030-04-02
AM-2600 MX	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	MX/a/2011/010140	MX 312376	2013-08-15	2030-04-02
AM-3200	Polyfarnesenes	US 12/552,278	US 8,048,976	2011-11-01	2029-07-23
AM-3201	Polyfarnesenes	US 13/235,530	US 8,314,196	2012-11-20	2029-09-01

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-3300	Adhesive Compositions Comprising Polyfarnesene	US 12/507,801	US 7,655,739	2010-02-02	2029-07-23
AM-3300 AU	Adhesive Compositions Comprising Polyfarnesene	AU 2009288675	AU 2009288675	2013-11-14	2029-09-03
AM-3300 BR	Adhesive Compositions Comprising Polyfarnesene	BR PI0918181-4			
AM-3300 CA	Adhesive Compositions Comprising Polyfarnesene	CA 2,735,255	CA 2,735,255	2017-02-21	2029-09-03
AM-3300 CN	Adhesive Compositions Comprising Polyfarnesene	CN 200980143983.1	CN ZL200980143983.1	2014-06-04	2029-09-03
AM-3300 EP-CH	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-DE	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-ES	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-FR	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-GB	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-IE	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-IT	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-NL	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 EP-SE	Adhesive Compositions Comprising Polyfarnesene	EP 09789248.3	EP 2334707	2012-02-01	2029-09-03
AM-3300 HK	Adhesive Compositions Comprising Polyfarnesene	HK 11106732.7	HK 1152711	2012-08-31	2029-09-03
AM-3300 IN	Adhesive Compositions Comprising Polyfarnesene	IN 2177/CHENP/2011	IN 286521	2017-08-22	2029-09-03
AM-3300 JP	Adhesive Compositions Comprising Polyfarnesene	JP 2011-526039	JP 5624986	2014-10-03	2029-09-03
AM-3300 KR	Adhesive Compositions Comprising Polyfarnesene	KR 10-2011-7007820	KR 10-1620991	2016-05-09	2029-09-03

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-3300 MX	Adhesive Compositions Comprising Polyfarnesene	MX/a/2011/002390	MX 294795	2012-01-16	2029-09-03
AM-3300 SG	Adhesive Compositions Comprising Polyfarnesene	SG 201101523-7	SG 169211	2012-10-15	2029-09-03
AM-3300 ZA	Adhesive Compositions Comprising Polyfarnesene	ZA 2011/01514	ZA 2011/01514	2012-04-25	2029-09-03
AM-3301	Compositions Comprising Polyfarnesene	US 12/694,120	US 7,759,444	2010-07-20	2029-07-23
AM-3302	Compositions Comprising Polyfarnesene	US 12/825,357	US 7,868,114	2011-01-11	2029-07-23
AM-3303	Compositions Comprising Polyfarnesene	US 12/825,364	US 7,868,115	2011-01-11	2029-07-23
AM-3400	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	US 12/978,061	US 7,919,605	2011-04-05	2030-12-23
AM-3410	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	US 13/220,553	US 9,018,364	2015-04-28	2030-12-23
AM-3410 AU	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	AU 2011296245	AU 2011296245	2015-04-30	2031-08-29
AM-3410 CN	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	CN 201180051803.4	CN 201180051803.4	2015-11-25	2031-08-29
AM-3410 EP-CH	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	EP 11755188.7	EP 2611923	2014-07-02	2031-08-29
AM-3410 EP-DE	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	EP 11755188.7	EP 2611923	2014-07-02	2031-08-29
AM-3410 EP-DK	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	EP 11755188.7	EP 2611923	2014-07-02	2031-08-29
AM-3410 EP-FR	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	EP 11755188.7	EP 2611923	2014-07-02	2031-08-29
AM-3410 EP-GB	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	EP 11755188.7	EP 2611923	2014-07-02	2031-08-29
AM-3410 EP-NL	Nucleic Acids, Compositions and	EP 11755188.7	EP 2611923	2014-07-02	2031-08-29

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
	Methods for the Excision of Target Nucleic Acids				
AM-3410 HK	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	HK 13108147.0	HK 1181070	2014-09-19	2031-08-29
AM-3410 JP	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	JP 2013-526203	JP 5883449	2016-02-12	2031-08-29
AM-3410 ZA	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	ZA 2013/01177	ZA 2013/01177	2014-04-30	2031-08-29
AM-3500	Squalane and Isosqualane Compositions and Methods For Preparing the Same	US 13/112,991	US 8,586,814	2013-11-19	2032-02-24
AM-3500 BR	Squalane and Isosqualane Compositions and Methods For Preparing the Same	BR 112012028932-2			2031-05-20
AM-3500 EP	Squalane and Isosqualane Compositions and Methods For Preparing the Same	EP 11724846.8			
AM-3500 JP	Squalane and Isosqualane Compositions and Methods For Preparing the Same	JP 2013-511388	JP 6351057	2018-06-15	2031-05-20
AM-3900 AU	Graft Copolymers of Polyfarnesenes with Condensation Polymers	AU 2011286019	AU 2011286019	2013-11-21	2031-07-29
AM-3900 BR	Graft Copolymers of Polyfarnesenes with Condensation Polymers	BR 1120120292153			
AM-3900 CA	Graft Copolymers of Polyfarnesenes with Condensation Polymers	CA 2,798,299	CA 2,798,299	2019-11-20	2031-07-29
AM-3900 CN	Graft Copolymers of Polyfarnesenes with Condensation Polymers	CN 201180035389.8	CN 103052664	2015-07-29	2031-07-29
AM-3900 EP-DE	Graft Copolymers of Polyfarnesenes with Condensation Polymers	EP 11746707.6	EP 2601229	2013-10-16	2031-07-29
AM-3900 EP-ES	Graft Copolymers of Polyfarnesenes with Condensation Polymers	EP 11746707.6	EP 2601229	2013-10-16	2031-07-29

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-3900 EP-FR	Graft Copolymers of Polyfarnesenes with Condensation Polymers	EP 11746707.6	EP 2601229	2013-10-16	2031-07-29
AM-3900 EP-GB	Graft Copolymers of Polyfarnesenes with Condensation Polymers	EP 11746707.6	EP 2601229	2013-10-16	2031-07-29
AM-3900 EP-IT	Graft Copolymers of Polyfarnesenes with Condensation Polymers	EP 11746707.6	EP 2601229	2013-10-16	2031-07-29
AM-3900 KR	Graft Copolymers of Polyfarnesenes with Condensation Polymers	KR 10-2012-7031759	KR 10-1836955	2018-03-05	2031-07-29
AM-3900 US	Graft Copolymers of Polyfarnesenes with Condensation Polymers	US 13/811,665	US 9,040,630	2015-05-26	2029-07-23
AM-4000	sesquiterpene synthase variants	US 13/363,588	US 8,236,512	2012-08-07	2032-02-01
AM-4000 AU	Sesquiterpene Synthase Variants	AU 2012212292	AU 2012212292	2014-05-24	2032-02-01
AM-4000 BR	Sesquiterpene Synthase Variants	BR 1120130195746			
AM-4000 CA	Sesquiterpene Synthase Variants	CA 2,826,554	CA 2,826,554	2015-03-31	2032-02-01
AM-4000 CN	Sesquiterpene Synthase Variants	CN 201280011458.6	CN ZL201280011458.6	2015-05-20	2032-02-01
AM-4000 EP-CH	Sesquiterpene Synthase Variants	EP 12742056.0	EP 2670846	2015-08-19	2032-02-01
AM-4000 EP-DE	Sesquiterpene Synthase Variants	EP 12742056.0	EP 2670846	2015-08-19	2032-02-01
AM-4000 EP-DK	Sesquiterpene Synthase Variants	EP 12742056.0	EP 2670846	2015-08-19	2032-02-01
AM-4000 EP-FR	Sesquiterpene Synthase Variants	EP 12742056.0	EP 2670846	2015-08-19	2032-02-01
AM-4000 EP-GB	Sesquiterpene Synthase Variants	EP 12742056.0	EP 2670846	2015-08-19	2032-02-01
AM-4000 EP-IE	Sesquiterpene Synthase Variants	EP 12742056.0	EP 2670846	2015-08-19	2032-02-01
AM-4000 EP-NL	Sesquiterpene Synthase Variants	EP 12742056.0	EP 2670846	2015-08-19	2032-02-01
AM-4000 IN	Sesquiterpene Synthase Variants	IN 7012/CHENP/2013			
AM-4000 JP	Sesquiterpene Synthase Variants	JP 2013-552590	JP 5580488	2014-07-18	2032-02-01
AM-4000 KR	Sesquiterpene Synthase Variants	KR 10-2013-7023002	KR 10-1420991	2014-07-11	2032-02-01
AM-4000 MX	Sesquiterpene Synthase Variants	MX/a/2013/008903	MX 346518	2017-03-23	2032-02-01
AM-4000 SG	Sesquiterpene Synthase Variants	SG 201305623-9			
AM-4000 ZA	Sesquiterpene Synthase Variants	ZA 2013/05797	ZA 2013/05797	2014-04-30	2032-02-01
AM-4400 BR	Olefins and Methods for Making the Same	BR PI1120130264179			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-4400 EP	Olefins and Methods for Making the Same	EP 12708189.1			
AM-4400 US	Olefins and Methods for Making the Same	US 14/112,235			
AM-4600	Production of Acetyl-Coenzyme A Derived Compounds	US 13/467,783	US 9,670,518	2017-06-06	2032-05-09
AM-4600 BR	Production of Acetyl-Coenzyme A Derived Compounds	BR 1120130285443			
AM-4600 CA	Production of Acetyl-Coenzyme A Derived Compounds	CA 2,832,979			
AM-4600 EP-CH	Production of Acetyl-Coenzyme A Derived Compounds	EP 12782714.5	EP 2707475	2015-09-30	2032-05-09
AM-4600 EP-DE	Production of Acetyl-Coenzyme A Derived Compounds	EP 12782714.5	EP 2707475	2015-09-30	2032-05-09
AM-4600 EP-DK	Production of Acetyl-Coenzyme A Derived Compounds	EP 12782714.5	EP 2707475	2015-09-30	2032-05-09
AM-4600 EP-FR	Production of Acetyl-Coenzyme A Derived Compounds	EP 12782714.5	EP 2707475	2015-09-30	2032-05-09
AM-4600 EP-GB	Production of Acetyl-Coenzyme A Derived Compounds	EP 12782714.5	EP 2707475	2015-09-30	2032-05-09
AM-4600 EP-NL	Production of Acetyl-Coenzyme A Derived Compounds	EP 12782714.5	EP 2707475	2015-09-30	2032-05-09
AM-4600 IN	Production of Acetyl-Coenzyme A Derived Compounds	IN 8980/CHENP/2013			
AM-4600 JP	Production of Acetyl-Coenzyme A Derived Compounds	JP 2014-510442	JP 5989098	2016-08-19	2032-05-09
AM-4600 MX	Production of Acetyl-Coenzyme A Derived Compounds	MX/a/2013/012871	MX 334188	2015-10-20	2032-05-09
AM-4600 ZA	Production of Acetyl-Coenzyme A Derived Compounds	ZA 2013/08393	ZA 2013/08393	2014-08-27	2032-05-09
AM-4800	Methods for Genomic Modification of Yeast	US 13/459,034	US 8,685,737	2014-04-01	2032-04-27
AM-4800 C1	Methods for Genomic Modification of Yeast	US 15/424,709			
AM-4800 D1	Methods for Genomic Modification of Yeast	US 14/178,203	US 9,701,971	2017-07-11	2032-04-27
AM-4800 AU	Methods for Genomic Modification of Yeast	AU 2012249390			2032-04-27
AM-4800 AU D1	Methods for Genomic Modification of Yeast	AU 2017204456			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-4800 BR	Methods for Genomic Modification of Yeast	BR 1120130255676			
AM-4800 CA	Methods for Genomic Modification of Yeast	CA 2,834,375			
AM-4800 CN	Methods for Genomic Modification of Yeast	CN 201280020323.6			2032-04-27
AM-4800 EP	Methods for Genomic Modification of Yeast	EP 12720058.2			
AM-4800 HK	Methods for Genomic Modification of Yeast	HK 14102329.2			
AM-4800 IN	Methods for Genomic Modification of Yeast	IN 8820/DELNP/2013			
AM-4800 JP	Methods for Genomic Modification of Yeast	JP 2014-508155	JP 6158170	2017-06-16	1932-04-27
AM-4800 JP D1	Methods for Genomic Modification of Yeast	JP 2016-235954			
AM-4800 KR	Methods for Genomic Modification of Yeast	KR 10-2013-7031551			
AM-4800 MX	Methods for Genomic Modification of Yeast	MX/a/2013/012479	MX 351043	2017-09-29	2032-04-27
AM-4800 SG	Methods for Genomic Modification of Yeast	SG 201307430-7	SG 194089	2016-04-26	2032-04-27
AM-4800 ZA	Methods for Genomic Modification of Yeast	ZA 2013/07225	ZA 2013/07225	2014-12-23	2032-04-27
AM-5200 BR	Base Oils and Methods for Making the Same	BR PI1120130264160			
AM-5200 EP-DE	Base Oils and Methods for Making the Same	EP 12706967.2	EP 2697186	2018-05-23	2033-05-23
AM-5200 EP-FR	Base Oils and Methods for Making the Same	EP 12706967.2	EP 2697186	2018-05-23	2033-05-23
AM-5200 EP-GB	Base Oils and Methods for Making the Same	EP 12706967.2	EP 2697186	2018-05-23	2033-05-23
AM-5200 US	Base Oils and Methods for Making the Same	US 14/112,238	US 9,862,906	2018-01-09	2034-11-13
AM-5400	Production of Acetyl-Coenzyme A Derived Isoprenoids	US 13/673,819	US 8,415,136	2013-04-09	2032-11-09
AM-5400 C1	Production of Acetyl-Coenzyme A Derived Isoprenoids	US 13/752,293	US 8,603,800	2013-12-10	2032-11-09
AM-5400 C2	Production of Acetyl-Coenzyme A Derived Isoprenoids	US 14/062,798	US 8,859,261	2014-10-14	2032-11-09
AM-5400 C3	Production of Acetyl-Coenzyme A Derived Isoprenoids	US 14/474,976	US 9,914,941	2018-03-13	2032-11-09
AM-5400 AU	Production of Acetyl-Coenzyme A Derived Isoprenoids	AU 2012335091	AU 2012335091	2016-09-29	1932-11-09
AM-5400 BR	Production of Acetyl-Coenzyme A Derived Isoprenoids	BR 1120140107505			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-5400 CA	Production of Acetyl-Coenzyme A Derived Isoprenoids	CA 2,853,679			
AM-5400 CN	Production of Acetyl-Coenzyme A Derived Isoprenoids	CN 201280066027.X	CN ZL201280066027.X	2016-10-12	2032-11-09
AM-5400 EP-BG	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-CH	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-DE	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-DK	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-ES	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-FR	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-GB	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-NL	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 EP-PT	Production of Acetyl-Coenzyme A Derived Isoprenoids	EP 12795948.4	EP 2776571	2017-04-12	2032-11-09
AM-5400 HK	Production of Acetyl-Coenzyme A Derived Isoprenoids	HK 14109484.8	HK 1196141B	2018-04-27	
AM-5400 IN	Production of Acetyl-Coenzyme A Derived Isoprenoids	IN 3791/CHENP/2014			
AM-5400 JP	Production of Acetyl-Coenzyme A Derived Isoprenoids	JP 2014-541353	JP 6073350	2017-01-13	2032-11-09
AM-5400 JP D1	Production of Acetyl-Coenzyme A Derived Isoprenoids	JP 2017-000210	JP 6461208	2019-01-11	2032-11-09
AM-5400 KR	Production of Acetyl-Coenzyme A Derived Isoprenoids	KR 10-2014-7015594			
AM-5400 MX	Production of Acetyl-Coenzyme A Derived Isoprenoids	MX/a/2014/005543	MX 346459	2017-03-22	2032-11-09
AM-5400 SG	Production of Acetyl-Coenzyme A Derived Isoprenoids	SG 11201402083X	SG 11201402083X	2016-06-20	2032-11-09



Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-5400 ZA	Production of Acetyl-Coenzyme A Derived Isoprenoids	ZA 2014/02989	ZA 2014/02989	2015-11-25	2032-11-09
AM-5500	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	US 13/442,625	US 8,332,160	2012-12-11	2032-04-09
AM-5500 AU	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	AU 2012340175	AU 2012340175	2018-08-23	
AM-5500 AU D1	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	AU 2018204935			
AM-5500 EP	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	EP 12806738.6			
AM-5500 HK	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	HK 15100305.3			
AM-5500 ZA	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	ZA 2014/03601	ZA 2014/03601	2016-01-27	2032-11-16
AM-5900 AU	Polymerization of Compositions Comprising a Farnesene	AU 2012370447	AU 2012370447	2016-05-05	2032-12-13
AM-5900 BR	Polymerization of Compositions Comprising a Farnesene	BR 1120140203610			
AM-5900 CA	Polymerization of Compositions Comprising a Farnesene	CA 2,864,663	CA 2,864,663	2016-04-12	2032-12-13
AM-5900 CN	Polymerization of Compositions Comprising a Farnesene	CN 201280070099.1	CN ZL201280070099.1	2016-10-12	2032-12-13
AM-5900 EP-CH	Polymerization of Compositions Comprising a Farnesene	EP 12812450.0	EP 2817342	2016-05-25	2032-12-13
AM-5900 EP-DE	Polymerization of Compositions Comprising a Farnesene	EP 12812450.0	EP 2817342	2016-05-25	2032-12-13
AM-5900 EP-FR	Polymerization of Compositions Comprising a Farnesene	EP 12812450.0	EP 2817342	2016-05-25	2032-12-13
AM-5900 EP-GB	Polymerization of Compositions Comprising a Farnesene	EP 12812450.0	EP 2817342	2016-05-25	2032-12-13
AM-5900 EP-NL	Polymerization of Compositions Comprising a Farnesene	EP 12812450.0	EP 2817342	2016-05-25	2032-12-13

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-5900 HK	Polymerization of Compositions Comprising a Farnesene	HK 15103446.7	HK 1202884	2017-01-06	2032-12-13
AM-5900 IN	Polymerization of Compositions Comprising a Farnesene	IN 6423/DELNP/2014			
AM-5900 JP	Polymerization of Compositions Comprising a Farnesene	JP 2014-558730	JP 6100248	2017-03-03	2032-12-13
AM-5900 MX	Polymerization of Compositions Comprising a Farnesene	MX/a/2014/010058	tba	2019-01-10	2032-12-13
AM-5900 ZA	Polymerization of Compositions Comprising a Farnesene	ZA 2014/05513	ZA 2014/05513	2015-11-25	2032-12-13
AM-6100 BR	Drilling Fluids Comprising Farnesane and/or Farnesene	BR 1120140122784			
AM-6300 AU	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	AU 2013299608			
AM-6300 BR	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	BR 1120150027245			
AM-6300 CA	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	CA 2,879,178			
AM-6300 CN	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	CN 201380041771.9	CN ZL201380041771.9	2018-05-29	
AM-6300 EP-DE	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	EP 13750244.9	EP 2882856	2017-12-20	
AM-6300 EP-FR	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	EP 13750244.9	EP 2882856	2017-12-20	
AM-6300 EP-GB	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	EP 13750244.9	EP 2882856	2017-12-20	
AM-6300 EP-NL	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	EP 13750244.9	EP 2882856	2017-12-20	
AM-6300 IN	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	IN 1204/CHENP/2015			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-6300 US	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	14/419,609			
AM-6310 AU	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	AU 2013397496			
AM-6310 BR	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	BR 1120160025261			
AM-6310 CA	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	CA 2,918,891			
AM-6310 CN	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	CN 201380080077.8			
AM-6310 EP	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	EP 13748255.0			
AM-6310 IN	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	IN 201627007153			
AM-6310 US	Methods for Stabilizing Production of Acetyl-Coenzyme A Derived Compounds	US 14/910,240			
AM-6400	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	US 14/214,062	US 9,410,214	2016-08-09	2034-09-02
AM-6400 AU	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	AU 2014227811	AU 2014227811	2018-09-20	2034-03-14
AM-6400 BR	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	BR 112015023089-0			
AM-6400 CA	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	CA 2,903,053			
AM-6400 CN	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	CN 201480025977.7			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-6400 EP	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	EP 14714149.3	EP 2971027	2019-01-30	2034-03-14
AM-6400 IN	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	IN 6134/CHENP/2015			
AM-6400 JP	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	JP 2016-502782			
AM-6400 KR	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	KR 10-2015-7028637			
AM-6400 MX	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	MX/a/2015/012365			
AM-6400 MY	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	MY PI2015703178			
AM-6400 ZA	Use of PPK and PTA for Production of Acetyl-Coenzyme A Derived Compounds	ZA 2015/06406	ZA 2015/06406	2017-01-25	2034-03-14
AM-6500	Methods for Genomic Integration	US 14/577,997	US 9,476,065	2016-10-25	2035-02-14
AM-6500 C1	Methods for Genomic Integration	US 15/261,727	US 10,041,092	2018-08-07	2035-01-13
AM-6500 C2	Methods for Genomic Integration	US 16/044,381			
AM-6500 AU	Methods for Genomic Integration	AU 2014368982			
AM-6500 CA	Methods for Genomic Integration	CA 2,933,902			
AM-6500 CN	Methods for Genomic Integration	CN 201480075698.1			
AM-6500 EP	Methods for Genomic Integration	EP 14831130.1			
AM-6500 HK	Methods for Genomic Integration	HK 17102835.6			
AM-6500 IN	Methods for Genomic Integration	IN 201617023246			
AM-6500 JP	Methods for Genomic Integration	JP 2016-540681			
AM-6500 KR	Methods for Genomic Integration	KR 10-2016-7019329			
AM-6500 MX	Methods for Genomic Integration	MX/a/2016/007797			
AM-6600	Solvent Compositions	US 14/702,607	US 10,071,034	2018-09-11	2035-11-06
AM-6600 EP	Solvent Compositions	EP 15723609.2			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-6600 EP-DE	Solvent Compositions	EP 15723609.2			
AM-6600 EP-FR	Solvent Compositions	EP 15723609.2			
AM-6600 EP-GB	Solvent Compositions	EP 15723609.2			
AM-6700 EP	High-Throughput Sequencing of DNA Assemblies	EP 15819931.5			
AM-6700 HK	High-Throughput Sequencing of DNA Assemblies	HK 18104624.6			
AM-6700 US	High-Throughput Sequencing of DNA Assemblies	US 15/532,865			
AM-6900 AU	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	AU 2016284689			
AM-6900 BR	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	BR112017027970-3			
AM-6900 CN	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	CN 201680048935.4			
AM-6900 EP	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	EP 16739303.2			
AM-6900 HK	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	HK 18113095.7			
AM-6900 US	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	US 15/738,555			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-6910 AU	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	AU 2016284696			
AM-6910 BR	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	BR112017027869-3			
AM-6910 CN	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	CN 201680048933.5			
AM-6910 EP	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	EP 16734852.3			
AM-6910 HK	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	HK 18113115.3			
AM-6910 US	Maltose Dependent Degrons, Maltose-Responsive Promoters, Stabilization Constructs, and Their Use in Production of Non-Catabolic Compounds	US 15/738,918			
AM-7000 CN	Compositions and Methods for Production of Myrcene	CN 201680076944.4			
AM-7000 HK	Compositions and Methods for Production of Myrcene	HK 19119666.6			
AM-7000 EP	Compositions and Methods for Production of Myrcene	EP 16794176.4			
AM-7000 IN	Compositions and Methods for Production of Myrcene	IN 201817018756			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-7000 US	Compositions and Methods for Production of Myrcene	US 15/771,888			
AM-7100 US	Compositions and Methods For Extraction of Botanical Compounds From Plants	US 15/763,029			
AM-7200 PCT	Compositions Containing Bio-Based Farnesene Or Compounds Derived Therefrom And Their Use In Consumer And Industrial Products	PCT/US2016/054542			
AM-7200 US	Compositions Containing Bio-Based Farnesene Or Compounds Derived Therefrom And Their Use In Consumer And Industrial Products	US 15/765,455			
AM-7300 EP	Compositions and Methods for Combinatorial Genomic Integration of Nucleic Acids	EP 17728315.7			
AM-7300 JP	Compositions and Methods for Combinatorial Genomic Integration of Nucleic Acids	JP 2018-560571			
AM-7300 US	Compositions and Methods for Combinatorial Genomic Integration of Nucleic Acids	US 16/302,079			
AM-7400 AU	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	AU 2017308143			
AM-7400 BR	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	BR 11 2018 074999 0			
AM-7400 CA	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	CA 3,031,162			
AM-7400 CN	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	tba			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-7400 EP	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	EP 17757641.0			
AM-7400 JP	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	JP 2019-507224			
AM-7400 KR	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D				
AM-7400 MX	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	MX/a/2019/001631			
AM-7400 MY	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	MY PI 2019000757			
AM-7400 RU	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D				
AM-7400 SG	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	SG 11201900930U			
AM-7400 US	UDP-Dependent Glycosyltransferase For High Efficiency Production of Rebaudioside D	US 16/323,756			
AM-7500 P1	Cells and Methods for Selection Based Assay	US 67/724,231			
AM-7600 PCT	Co-Production of Isoprenoids	PCT/US2018/015326			
AM-7700 PCT	Pisum Sativum Kaurene Oxidase for High Efficiency Production of Rebaudiosides	PCT/US2018/046359			
AM-7800 P2	Methods for Producing Full-Length Antibodies	US 62/667,195			
AM-7800 PCT	Methods for Producing Full-Length Antibodies	PCT/US2018/050592			



Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-7900 P2	Methods for Genomic Integration in Pichia and Other Host Cells	US 62/666,923			
AM-7900 PCT	Methods for Genomic Integration in Pichia and Other Host Cells	PCT/US2018/050613			
AM-8000 P2	Methods of Genomic Integration for Host Cells Including Hansenula and Arxula	US 62/667,020			
AM-8000 PCT	Methods of Genomic Integration for Host Cells Including Hansenula and Arxula	PCT/US2018/050706			
AM-8100 P2	Methods for Genomic Integration for Host Cells Including Kluyveromyces	US 62/667,000			
AM-8100 PCT	Methods for Genomic Integration for Host Cells Including Kluyveromyces	PCT/US2018/050732			
AM-8200 P2	Methods for Genetic Engineering Kluyveromyces Host Cells for Production and Secretion of Antibodies	US 62/667,089			
AM-8200 PCT	Methods for Genetic Engineering Kluyveromyces Host Cells for Production and Secretion of Antibodies	PCT/US2018/050635			
AM-8400 P1	Compounds, Compositions, and Methods for Recovering Water-Immiscible Compounds from Microbial Biomass	US 62/692,536			
AM-8500 P1	Methods and Compositions for Providing Fermentation Feed Rates	US 62/697,167			
AM-8600 P1	Synthesis of E,E-Farnesol, Farnesyl Acetate and Squalene from Farnesene via Farnesyl Chloride	US 62/682,616			
AM-8700 EP P1	Process for Recovering Isoprenoids Produced by Microorganisms	EP 17306050			
AM-8700 PCT	Process for Recovering Isoprenoids Produced by Microorganisms	PCT/EP2018/007084 4			
AM-8800 EP P1	Process for the Recovery of Fermentation Products	EP 17290101			
AM-8800 PCT	Process for the Recovery of Fermentation Products	PCT/EP2018/017031 5			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AM-8900 P1	Stevia Rebaudiana Kaurenoic Acid Hydroxylase for High Efficiency Production of Rebaudiosides	US 62/745,900			
AM-9000	Biosynthesis of Compounds in Yeast	US 16/198,545			
AM-9300 P1	ABC Transporters for the High Efficiency Production of Steviol Glycosides	US 62/796,228			
AR- 100	Method of Producing Geranylgeraniol	US 09/350,275	US 6,531,303	2003-03-11	2019-07-06
AR- 100 C1A	Production of Farnesol and Geranylgeraniol	US 09/909,558	US 6,689,593	2004-02-10	2019-07-06
AR- 100 C2	Production of Isoprenoids	US 11/753,399	US 8,241,888	2012-08-14	2019-07-06
AR- 100 C2 D1	Production of Isoprenoids	US 12/510,041	US 8,236,552	2012-08-07	2019-07-06
AR- 100 C3	Production of Isoprenoids	US 11/753,254	US 7,842,497	2010-11-30	2019-07-06
AR- 100 C3 C1	Production of Isoprenoids	US 12/942,723	US 7,927,861	2011-04-19	2019-07-06
AR- 100 C4	Production of Isoprenoids	US 11/753,301	US 7,838,279	2010-11-23	2019-07-06
AR- 100 C4 C1	Production of Isoprenoids	US 12/942,809	US 7,927,862	2011-04-19	2019-07-06
AR- 100 C4 C3	Production of Isoprenoids	US 13/865,072	US 9,102,954	2015-08-11	2019-07-06
AR- 100 C5	Production of Isoprenoids	US 11/752,933	US 7,718,417	2010-05-18	2019-07-06
AR- 100 C6	Production of Isoprenoids	US 11/752,931	US 7,732,161	2010-06-08	2019-07-06
AR- 100 C6C1	Production of Isoprenoids	US 14/788,402			
AR- 100 CA	Method of Vitamin Production	CA 2,331,343	CA 2,331,343	2014-01-14	2019-07-06
AR- 100 CA D1	Production of Isoprenoid in Recombinant Yeast	CA 2,831,321	CA 2,831,321	2018-05-15	
AR- 100 EP1-CH	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-DE	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-DK	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-ES	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-FR	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-GB	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-IE	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AR- 100 EP1-IT	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-LU	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-MC	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-NL	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP1-SE	Production of Farnesol and Geranylgeraniol	EP 08003596.7	EP 1947189	2010-12-01	2019-07-06
AR- 100 EP2-CH	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-DE	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-DK	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-ES	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-FR	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-GB	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-IE	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-IT	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-LU	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-MC	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-NL	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP2-SE	Production of Farnesol and Geranylgeraniol	EP 09004155.9	EP 2100963	2011-12-14	2019-07-06
AR- 100 EP3-CH	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-DE	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-DK	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-ES	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-FR	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-GB	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-IE	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-IT	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-LU	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
AR- 100 EP3-MC	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-NL	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 EP3-SE	Production of Farnesol and Geranylgeraniol	EP 10180179.3	EP 2305825	2015-01-14	2019-07-06
AR- 100 JP	Production of Farnesol and Geranylgeraniol	JP 2000-558056	JP 4,579,415	2010-09-03	2019-07-06
AR- 100 MX	Production of Farnesol and Geranylgeraniol	MX PA/a/2001/000216	MX 219130	2004-02-10	2019-07-06
AR- 100 MX C1	Production of Farnesol and Geranylgeraniol	MX PA/a/2004/002408	MX 276941	2010-06-28	2019-07-06
AR- 100 MX C1D1	Production of Farnesol and Geranylgeraniol	MX/a/2008/011194	MX 322030	2014-07-16	2019-07-06
AR- 100 MX C1D2	Production of Farnesol and Geranylgeraniol	MX/a/2013/010844			
DR- 100	Preparation of Trans, Trans Muconic Acid and Trans, Trans Muconates	US 12/816,481	US 8,426,639	2013-04-23	2031-02-11
DR-1100 BR	Methods for Producing Isomers of Muconic Acid and Muconate Salts	BR 112012016855-0			
DR-1100 CA	Methods for Producing Isomers of Muconic Acid and Muconate Salts	CA 2,786,405			
DR-1100 CN	Methods for Producing Isomers of Muconic Acid and Muconate Salts	CN 201180012960.4	CN 102985537B	2015-11-25	2031-01-10
DR-1100 EP-CH	Methods for Producing Isomers of Muconic Acid and Muconate Salts	EP 11700591.8	EP 2521770	2015-11-25	2031-01-10
DR-1100 EP-DE	Methods for Producing Isomers of Muconic Acid and Muconate Salts	EP 11700591.8	EP 2521770	2015-11-25	2031-01-10
DR-1100 EP-DK	Methods for Producing Isomers of Muconic Acid and Muconate Salts	EP 11700591.8	EP 2521770	2015-11-25	2031-01-10
DR-1100 EP-FR	Methods for Producing Isomers of Muconic Acid and Muconate Salts	EP 11700591.8	EP 2521770	2015-11-25	2031-01-10
DR-1100 EP-GB	Methods for Producing Isomers of Muconic Acid and Muconate Salts	EP 11700591.8	EP 2521770	2015-11-25	2031-01-10
DR-1100 EP-NL	Methods for Producing Isomers of Muconic Acid and Muconate Salts	EP 11700591.8	EP 2521770	2015-11-25	2031-01-10
DR-1100 IN	Methods for Producing Isomers of Muconic Acid and Muconate Salts	IN 2007/KOLNP/2012			
DR-1100 MX	Methods for Producing Isomers of Muconic Acid and Muconate Salts	MX/a/2012/007944	MX 333523	2015-09-25	2031-01-10

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
DR-1100 US	Methods for Producing Isomers of Muconic Acid and Muconate Salts	US 13/518,534	US 8,809,583	2014-08-19	2031-01-10
UC- 100	Biosynthesis of Isopentenyl Pyrophosphate	US 10/006,909	US 7,172,886	2007-02-06	2022-06-23
UC- 100 C1	Isolated Mevalonate Pathway Enzyme Nucleic Acids	US 11/469,587	US 7,667,017	2010-02-23	2022-07-06
UC- 100 C2	Methods for Synthesizing Mevalonate	US 11/610,690	US 7,622,283	2009-11-24	2021-12-06
UC- 100 D1	Biosynthesis of Isopentenyl Pyrophosphate	US 11/610,337	US 7,622,282	2009-11-24	2021-12-06
UC- 100 D2	Host Cells for Production of Isoprenoid Compounds	US 11/610,686	US 7,736,882	2010-06-15	2022-01-11
UC- 100 D2C1	Host Cells for Production of Isoprenoid Compounds	US 12/576,068	US 7,915,026	2011-03-29	2021-12-06
UC- 100 D2C2	Host Cells for Production of Isoprenoid Compounds	US 13/027,517	US 8,288,147	2012-10-16	2021-12-06
UC- 110	Biosynthesis of Amorpha-4,11-diene	US 10/411,066	US 7,192,751	2007-03-20	2021-12-06
UC- 400	Method for Enhancing Production of Isoprenoid Compounds	US 11/134,705	US 7,183,089	2007-02-27	2025-05-20
UC- 400 C1	Method for Enhancing Production of Isoprenoid Compounds	US 11/624,094	US 7,670,825	2010-03-02	2026-06-21
UC- 400 AU	Method for Enhancing Production of Isoprenoid Compounds	AU 2005327292	AU 2005327292	2011-02-17	2025-05-20
UC- 400 BR	Method for Enhancing Production of Isoprenoid Compounds	BR PI0510115-8			
UC- 400 CA	Method for Enhancing Production of Isoprenoid Compounds	CA 2,567,547	CA 2,567,547	2012-10-23	2025-05-20
UC- 400 EP-DE	Method for Enhancing Production of Isoprenoid Compounds	EP 05857432.8	EP 1765418	2011-12-14	2025-05-20
UC- 400 EP-ES	Method for Enhancing Production of Isoprenoid Compounds	EP 05857432.8	EP 1765418	2011-12-14	2025-05-20
UC- 400 EP-FR	Method for Enhancing Production of Isoprenoid Compounds	EP 05857432.8	EP 1765418	2011-12-14	2025-05-20
UC- 400 EP-GB	Method for Enhancing Production of Isoprenoid Compounds	EP 05857432.8	EP 1765418	2011-12-14	2025-05-20

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
UC- 400 EP-IE	Method for Enhancing Production of Isoprenoid Compounds	EP 05857432.8	EP 1765418	2011-12-14	2025-05-20
UC- 400 EP-IT	Method for Enhancing Production of Isoprenoid Compounds	EP 05857432.8	EP 1765418	2011-12-14	2025-05-20
UC- 400 JP	Method for Enhancing Production of Isoprenoid Compounds	JP 2007-527501	JP 4,926,061	2012-05-09	2025-05-20
UC- 400 MX	Method for Enhancing Production of Isoprenoid Compounds	MX PA/a/2006/013502	MX 279706	2010-10-05	2025-05-20
UC- 400 VN	Method for Enhancing Production of Isoprenoid Compounds	VN 1-2006-02031	VN 9908	2011-12-15	2025-05-20
UC- 400 ZA	Method for Enhancing Production of Isoprenoid Compounds	ZA 2006/10171	ZA 2006/10171	2008-04-30	2025-05-20
UC- 500 AU	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	AU 2005269556	AU 2005269556	2012-02-09	2025-07-21
UC- 500 BR	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	BR PI0513837-0			
UC- 500 CA	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	CA 2,574,593	CA 2,574,593	2016-07-05	2025-07-21
UC- 500 EP-DE	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	EP 05775484.8	EP 1778831	2012-05-23	2025-07-21
UC- 500 EP-ES	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	EP 05775484.8	EP 1778831	2012-05-23	2025-07-21
UC- 500 EP-FR	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	EP 05775484.8	EP 1778831	2012-05-23	2025-07-21
UC- 500 EP-GB	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	EP 05775484.8	EP 1778831	2012-05-23	2025-07-21
UC- 500 EP-IT	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	EP 05775484.8	EP 1778831	2012-05-23	2025-07-21
UC- 500 JP	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	JP 2007-523676	JP 5590769	2014-08-08	2025-07-21

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
UC- 500 MX	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	MX/a/2007/000973	MX 303040	2012-09-04	2025-07-21
UC- 500 US	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	US 11/571,315	US 8,828,684	2014-09-09	2028-10-11
UC- 500 US C1	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	US 14/451,056	US 9,809,829	2017-11-07	2028-02-19
UC- 500 US C2	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	US 15/722,844			
UC- 500 VN	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	VN 1-2007-00356	VN 11485	2013-06-10	2025-07-21
UC- 500 ZA	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	ZA 2007/00753	ZA 2007/00753	2008-05-28	2025-07-21
UC- 600 BR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	BR PI0612411-9			
UC- 600 CA	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	CA 2,613,469	CA 2613469	2014-08-12	2026-06-29
UC- 600 CN	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	CN 200680024666.4	CN ZL200680024666.4	2013-09-04	
UC- 600 CN D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	CN 201310335874.8	CN ZL201310335874.8	2016-08-10	
UC- 600 CN D2	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	CN 201610412819.8			
UC- 600 CN D3	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	CN 201710271576.5			
UC- 600 EP-BG	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
UC- 600 EP-CH	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-CZ	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-DE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-DK	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-ES	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-FR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-GB	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-IE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-IT	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-NL	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-PT	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-SE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29
UC- 600 EP-TR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 06785959.5	EP 1919514	2012-05-16	2026-06-29



Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
UC- 600 EP-BG D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-CH D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-DE D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-ES D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-FR D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-GB D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-IE D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-IT D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 EP-TR D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	EP 12158465.0	EP 2489672	2017-01-18	2026-06-29
UC- 600 HK D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	HK 17107981.7			
UC- 600 IL	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	IL 188376	IL 188376	2013-04-01	2026-06-29
UC- 600 IN	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	IN 0527/DELNP/2008	IN 305449	2019-01-08	
UC- 600 IN D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	IN 201718046361			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
UC- 600 JP	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	JP 2008-519611			
UC- 600 KR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	KR 10-2008-7002992	KR 10-1444090000	2014-09-18	2026-06-29
UC- 600 KR D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	KR 10-2013-7011897	KR 10-14873040000	2015-01-22	2026-06-29
UC- 600 MX	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	MX/a/2008/000200	MX 305636	2012-11-29	2026-06-29
UC- 600 MX D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	MX/a/2012/007818	MX 333465	2015-09-24	
UC- 600 SG	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	SG 200800019-2	SG 138880	2011-11-15	2026-06-29
UC- 600 SG D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	SG 201108140-3	SG 176459	2015-05-26	2026-06-29
UC- 600 US .	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	US 11/917,875	US 8,163,980	2012-04-24	2028-06-26
UC- 600 US D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	US 13/426,387	US 8,759,632	2014-06-24	2026-06-29
UC-1100 BR	Production of Isoprenoids and Precursors Thereof	BR PI0716954-0			
UC-1100 EP-CH	Production of Isoprenoids and Precursors Thereof	EP 07838895.6	EP 2066778	2016-01-27	2027-09-25
UC-1100 EP-DE	Production of Isoprenoids and Precursors Thereof	EP 07838895.6	EP 2066778	2016-01-27	2027-09-25
UC-1100 EP-DK	Production of Isoprenoids and Precursors Thereof	EP 07838895.6	EP 2066778	2016-01-27	2027-09-25
UC-1100 EP-FR	Production of Isoprenoids and Precursors Thereof	EP 07838895.6	EP 2066778	2016-01-27	2027-09-25
UC-1100 EP-GB	Production of Isoprenoids and Precursors Thereof	EP 07838895.6	EP 2066778	2016-01-27	2027-09-25

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
UC-1100 EP-NL	Production of Isoprenoids and Precursors Thereof	EP 07838895.6	EP 2066778	2016-01-27	2027-09-25
UC-1100 EP D1	Production of Isoprenoids and Precursors Thereof	EP 15196123.2			
UC-1100 IN	Production of Isoprenoids and Precursors Thereof	IN 2242/DELNP/2009	IN 271189	2016-02-08	2027-09-25
UC-1100 US	Production of Isoprenoids and Precursors Thereof	US 12/439,812	US 8,257,957	2012-09-04	2027-10-20
GV- 100 BR	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	BR112016008531-0			
GV- 100 CN	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	CN 201480058480.5			
GV- 100 EP	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	EP 14787207.1			
GV- 100 IN	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	IN 201647014032			
GV- 100 IL	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	IL 244929			
GV- 100 JP	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	JP 2016-549636			
GV- 100 MX	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	MX/a/2016/005053			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
GV- 100 SG	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	SG 11201602725U			
GV- 100 US	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	US 15/031,158	US 9,718,741	2017-08-01	2034-10-24
GV- 100 US C1	Cyclopropanation Process Using Diazomethane from N-methyl-N-nitroso-urea provided by solvent extraction	US 15/630,060			
GV- 200 BR	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	BR112016008895-6			
GV- 200 CN	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	CN 201480058481.X	CN ZL201480058481.X	2018-02-06	2034-10-24
GV- 200 EP-CH	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	EP 14796445.6	EP 3060542	2018-02-21	2034-10-24
GV- 200 EP-DE	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	EP 14796445.6	EP 3060542	2018-02-21	2034-10-24
GV- 200 EP-ES	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	EP 14796445.6	EP 3060542	2018-02-21	2034-10-24
GV- 200 EP-FR	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	EP 14796445.6	EP 3060542	2018-02-21	2034-10-24

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
GV- 200 EP-GB	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	EP 14796445.6	EP 3060542	2018-02-21	2034-10-24
GV- 200 EP-IT	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	EP 14796445.6	EP 3060542	2018-02-21	2034-10-24
GV- 200 IN	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	IN 201647014077			
GV- 200 IL	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	IL 244928			
GV- 200 JP	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	JP 2016-549637			
GV- 200 MX	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	tba			
GV- 200 SG	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	SG 11201602722Y		2018-08-20	2034-10-24
GV- 200 US	Preparation of Homoallylic Compounds By Reaction of Cyclopropylvinyl Precursors With Brondstedt Acids	US 15/031,132	US 15/031,132	2018-10-24	2034-10-24
KU- 100 JP (non-PCT)	Rubber Composition and Tire	2013-141818	tba	tba	
KU- 100 BR	Rubber Composition and Tire	BR112014007431-3			
KU- 100 CA	Rubber Composition and Tire	2837545	2837545	2014-06-10	

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU- 100 CN	Rubber Composition and Tire	2.0128E+11	ZL201280039788.6	2016-06-15	
KU- 100 CN 2	Rubber Composition and Tire	201610342576.5			
KU- 100 EP-CZ	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-DE	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-ES	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-FI	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-FR	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-GB	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-IT	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-NL	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-PT	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 EP-SE	Rubber Composition and Tire	12836811.5	2762525	2016-09-14	
KU- 100 IN	Rubber Composition and Tire	2317/CHENP/2014			
KU- 100 JP	Rubber Composition and Tire	2013-502318	5314811	2013-07-12	
KU- 100 KR	Rubber Composition and Tire	2013-7031920	1388404	2014-04-16	
KU- 100 RU	Rubber Composition and Tire	2014112227			
KU- 100 TW	Rubber Composition and Tire	101134698	1471375	2015-02-01	
KU- 100 US	Rubber Composition and Tire	14/125461	8912269	2014-12-16	
KU- 100 US 2	Rubber Composition and Tire	14/537156	9534111	2017-01-03	
KU- 200 JP (non-PCT)	Rubber Composition and Tire	2013-141821			
KU- 200 BR	Rubber Composition and Tire	BR112014007430-5			
KU- 200 CA	Rubber Composition and Tire	2837547	2837547	2014-06-10	
KU- 200 CN	Rubber Composition and Tire	201280039819.8			
KU- 200 CN 2	Rubber Composition and Tire	201510994046.4			
KU- 200 EP-CZ	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-DE	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-ES	Rubber Composition and Tire	12835338	2762524	2016-09-14	

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU- 200 EP-FI	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-FR	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-GB	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-IT	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-NL	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-PT	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 EP-SE	Rubber Composition and Tire	12835338	2762524	2016-09-14	
KU- 200 IN	Rubber Composition and Tire	2316/CHENP/2014			
KU- 200 JP	Rubber Composition and Tire	2013-502319	5314812	2013-07-12	
KU- 200 KR	Rubber Composition and Tire	2013-7031921	1414302	2014-06-25	
KU- 200 RU	Rubber Composition and Tire	2014112226			
KU- 200 TW	Rubber Composition and Tire	101134697	1441867	2014-06-21	
KU- 200 US	Rubber Composition and Tire	14/233052	8785542	2014-07-22	
KU- 300 JP (non-PCT)	Rubber Composition and Tire	2013-144020			
KU- 300 BR	Rubber Composition and Tire	BR112014020827-1			
KU- 300 CA	Rubber Composition and Tire	2865378			
KU- 300 CN	Rubber Composition and Tire	201380010563.20	tba	tba	
KU- 300 CN 2	Rubber Composition and Tire	201610743525.3			
KU- 300 EP	Rubber Composition and Tire	13751718.1			
KU- 300 IN	Rubber Composition and Tire	6340/CHENP/2014			
KU- 300 JP	Rubber Composition and Tire	2013-529896	5617040	2014-09-19	
KU- 300 KR	Rubber Composition and Tire	2014-7023404			
KU- 300 RU	Rubber Composition and Tire	2014138498			
KU- 300 TW	Rubber Composition and Tire	102106117	tba	tba	
KU- 300 US	Rubber Composition and Tire	14/380534	9228077	2016-01-05	
KU- 400 JP (non-PCT)	Copolymer, Rubber Composition Using Same, and Tire	2013-171772			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU- 400 BR	Copolymer, Rubber Composition Using Same, and Tire	BR112014021695-9			
KU- 400 CA	Copolymer, Rubber Composition Using Same, and Tire	2869390			
KU- 400 CN	Copolymer, Rubber Composition Using Same, and Tire	201380018389.6			
KU- 400 EP	Copolymer, Rubber Composition Using Same, and Tire	13771874.8	2835386	2017-01-11	
KU- 400 IN	Copolymer, Rubber Composition Using Same, and Tire	7394/CHENP/2014			
KU- 400 JP	Copolymer, Rubber Composition Using Same, and Tire	2013-536738	5555814	2014-06-06	
KU- 400 KR	Copolymer, Rubber Composition Using Same, and Tire	2014-7027991			
KU- 400 RU	Copolymer, Rubber Composition Using Same, and Tire	2014140206			
KU- 400 TW	Copolymer, Rubber Composition Using Same, and Tire	102112120			
KU- 400 US	Copolymer, Rubber Composition Using Same, and Tire	14/390581			
KU- 500 JP (non-PCT)	Copolymer, Rubber Composition Using Same, and Tire	2013-171782			
KU- 500 BR	Copolymer, Rubber Composition Using Same, and Tire	BR112014024729-3			
KU- 500 CA	Copolymer, Rubber Composition Using Same, and Tire	2869393			
KU- 500 CN	Copolymer, Rubber Composition Using Same, and Tire	201380018349.1			
KU- 500 EP	Copolymer, Rubber Composition Using Same, and Tire	13772956.2	2835387	2016-12-28	
KU- 500 IN	Copolymer, Rubber Composition Using Same, and Tire	7396/CHENP/2014			
KU- 500 JP	Copolymer, Rubber Composition Using Same, and Tire	2013-536732	5555813	2014-06-06	
KU- 500 KR	Copolymer, Rubber Composition Using Same, and Tire	2014-7027990			



Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU- 500 RU	Copolymer, Rubber Composition Using Same, and Tire	2014140208			
KU- 500 TW	Copolymer, Rubber Composition Using Same, and Tire	102112121			
KU- 500 US	Copolymer, Rubber Composition Using Same, and Tire	14/390660			
KU- 600 JP (non-PCT)	Copolymer, Rubber Composition Using Same, and Tire	2013-150619			
KU- 600 BR	Copolymer, Rubber Composition Using Same, and Tire	BR112014024788-9			
KU- 600 CA	Copolymer, Rubber Composition Using Same, and Tire	2869386			
KU- 600 CN	Copolymer, Rubber Composition Using Same, and Tire	201380018307.8			
KU- 600 EP	Copolymer, Rubber Composition Using Same, and Tire	13771812.8			
KU- 600 IN	Copolymer, Rubber Composition Using Same, and Tire	7393/CHENP/2014			
KU- 600 JP	Copolymer, Rubber Composition Using Same, and Tire	2013-529895	5400989	2013-11-01	
KU- 600 KR	Copolymer, Rubber Composition Using Same, and Tire	2014-7027989			
KU- 600 RU	Copolymer, Rubber Composition Using Same, and Tire	2014140207			
KU- 600 TW	Copolymer, Rubber Composition Using Same, and Tire	102112119			
KU- 600 US	Copolymer, Rubber Composition Using Same, and Tire	14/390637			
KU- 700 CA	Hydrogenated Block Copolymer and Method for Producing Same	2875448			
KU- 700 CN	Hydrogenated Block Copolymer and Method for Producing Same	201380029187.1			
KU- 700 EP	Hydrogenated Block Copolymer and Method for Producing Same	13801356			
KU- 700 JP	Hydrogenated Block Copolymer and Method for Producing Same	2014-519972			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU- 700 KR	Hydrogenated Block Copolymer and Method for Producing Same	2014-7034236			
KU- 700 TW	Hydrogenated Block Copolymer and Method for Producing Same	102120232			
KU- 700 US	Hydrogenated Block Copolymer and Method for Producing Same	14/405213	9353201	2016-05-31	
KU- 800 CA	Viscosity Index Improver, Method For Producing Same, and Oil Composition	2888668	2888668	2016-10-18	
KU- 800 CN	Viscosity Index Improver, Method For Producing Same, and Oil Composition	201480002724.8			
KU- 800 EP	Viscosity Index Improver, Method For Producing Same, and Oil Composition	14763262.4			
KU- 800 JP	Viscosity Index Improver, Method For Producing Same, and Oil Composition	2014-533732	5671658	2014-12-26	
KU- 800 KR	Viscosity Index Improver, Method For Producing Same, and Oil Composition	2015-7009928	1552090	2015-09-03	
KU- 800 TW	Viscosity Index Improver, Method For Producing Same, and Oil Composition	103108067			
KU- 800 US	Viscosity Index Improver, Method For Producing Same, and Oil Composition	14/436700			
KU- 900 CA	Laminate, Protective Film and Method for Manufacturing Laminate	2907822			
KU- 900 CN	Laminate, Protective Film and Method for Manufacturing Laminate	201480018428.7			
KU- 900 EP	Laminate, Protective Film and Method for Manufacturing Laminate	14774052.6			
KU- 900 JP	Laminate, Protective Film and Method for Manufacturing Laminate	2015-508268			
KU -900 KR	Laminate, Protective Film and Method for Manufacturing Laminate	2015-7026291			
KU- 900 TW	Laminate, Protective Film and Method for Manufacturing Laminate	103111161			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU- 900 US	Laminate, Protective Film and Method for Manufacturing Laminate	14/779420			
KU-1000 JP (non-PCT)	Rubber Composition, Vulcanized Rubber and Tire	2014-061230			
KU-1100 CN	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	201480017895.8			
KU-1100 KR	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	2015-7026353			
KU-1100 JP	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	2015-508763			
KU-1100 TW	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	103111713			
KU-1200 JP	Laminate	2013-120801			
KU-1300	Rubber Composition and Tire				
KU-1300 CA	Rubber Composition and Tire	2921890			
KU-1300 CN	Rubber Composition and Tire	201480046655			
KU-1300 EP	Rubber Composition and Tire	14838208.8			
KU-1300 JP	Rubber Composition and Tire	2015-532821			
KU-1300 KR	Rubber Composition and Tire	2016-7004637			
KU-1300 TW	Rubber Composition and Tire	103127496			
KU-1300 US	Rubber Composition and Tire	14/913638			
KU-1400 CN	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	201480052669.3			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU-1400 JP	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	2015-538930			
KU-1400 KR	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	2016-7007537			
KU-1400 TW	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	103111707			
KU-1500 JP	Resin Composition, Cured Product Obtained by Curing Same, and Optical Adhesive Comprising Resin Composition	2013-205552			
KU-1600 CA	Thermoplastic Elastomer Composition and Molded Body	2910534			
KU-1600 CN	Thermoplastic Elastomer Composition and Molded Body	201480031125.9			
KU-1600 EP	Thermoplastic Elastomer Composition and Molded Body	14847738.3			
KU-1600 JP	Thermoplastic Elastomer Composition and Molded Body	2015-508342	5763865	2015-06-19	
KU-1600 KR	Thermoplastic Elastomer Composition and Molded Body	2015-7031120			
KU-1600 TW	Thermoplastic Elastomer Composition and Molded Body	103133849	1535774	2016-06-01	
KU-1600 US	Thermoplastic Elastomer Composition and Molded Body	14/787923			
KU-1700 CA	Polyolefin-Based Resin Composition and Molded Body	2910452			
KU-1700 CN	Polyolefin-Based Resin Composition and Molded Body	201480031015.2			
KU-1700 EP	Polyolefin-Based Resin Composition and Molded Body	14849722.5			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU-1700 JP	Polyolefin-Based Resin Composition and Molded Body	2015-508343	5763866	2015-06-19	
KU-1700 KR	Polyolefin-Based Resin Composition and Molded Body	2015-7031138	tba	tba	
KU-1700 US	Polyolefin-Based Resin Composition and Molded Body	14/888003			
KU-1700 TW	Polyolefin-Based Resin Composition and Molded Body	103133850	1537332	2016-06-11	
KU-1800 JP	Rubber Composition and Tire	2013-210870			
KU-1900 JP	Rubber Composition and Tire	2013-210879			
KU-2000 CA	Sealant	2933261			
KU-2000 CN	Sealant	201480067984.3			
KU-2000 EP	Sealant	14869628.9			
KU-2000 JP	Sealant	2015-552500			
KU-2000 KR	Sealant	2016-7015381			
KU-2000 TW	Sealant	103143347			
KU-2000 US	Sealant	15/103168			
KU-2100 CA	Resin Composition, Molded Article, and Resin Modifier	2932705			
KU-2100 CN	Resin Composition, Molded Article, and Resin Modifier	201480066845.9			
KU-2100 EP	Resin Composition, Molded Article, and Resin Modifier	14869455.7			
KU-2100 JP	Resin Composition, Molded Article, and Resin Modifier	2015-552499			
KU-2100 KR	Resin Composition, Molded Article, and Resin Modifier	2016-7014923			
KU-2100 TW	Resin Composition, Molded Article, and Resin Modifier	103143348			
KU-2100 US	Resin Composition, Molded Article, and Resin Modifier	15/103196			
KU-2200 CA	Thermoplastic Elastomer Composition, Molded Article, and Adhesive Agent	2933267			
KU-2200 CN	Thermoplastic Elastomer Composition, Molded Article, and Adhesive Agent	201480067838.0			
KU-2200 EP	Thermoplastic Elastomer Composition, Molded	14869642			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
	Article, and Adhesive Agent				
KU-2200 JP	Thermoplastic Elastomer Composition, Molded Article, and Adhesive Agent	2015-552501			
KU-2200 KR	Thermoplastic Elastomer Composition, Molded Article, and Adhesive Agent	2016-7015435			
KU-2200 TW	Thermoplastic Elastomer Composition, Molded Article, and Adhesive Agent	103143349			
KU-2200 US	Thermoplastic Elastomer Composition, Molded Article, and Adhesive Agent	15/103218			
KU-2300 CA	Aqueous Emulsion, Thin Molded Article, and Method for Producing Thin Molded Article	2938654			
KU-2300 CN	Aqueous Emulsion, Thin Molded Article, and Method for Producing Thin Molded Article	201580007212.5			
KU-2300 EP	Aqueous Emulsion, Thin Molded Article, and Method for Producing Thin Molded Article	15745993.4			
KU-2300 JP	Aqueous Emulsion, Thin Molded Article, and Method for Producing Thin Molded Article	2015-530195	5829782	2015-10-30	
KU-2300 KR	Aqueous Emulsion, Thin Molded Article, and Method for Producing Thin Molded Article	2016-7021158			
KU-2300 TW	Aqueous Emulsion, Thin Molded Article, and Method for Producing Thin Molded Article	104104154			
KU-2300 US	Aqueous Emulsion, Thin Molded Article, and Method for Producing Thin Molded Article	15/116774			
KU-2400 JP	Vulcanized Rubber, Method for Producing Same, and Tire	2014-153908			
KU-2500 JP	Rubber Composition Containing Modified Polyfarnesenes, Tire and Method for Producing Same	2014-163568			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KU-2600 JP	Modified Polyfarnesene, Method for Producing Same, Rubber Composition and Tire	2014-163569			
KU-2700 JP	Rubber Composition For Vibration Isolation Structure and Vibratio Isolation Structure Using Same	2014-207470			
KU-2800 PCT	Sealing Material Composition	PCT/JP2015/080271			
KU-2800 TW	Sealing Material Composition	104135394			
KU-2900 JP	Rubber Composition and Tire	2014-225517			
KU-3000 JP	Thermoplastic Elastomer Composition, Crosslinked Material, Molded Article, Part, Weather Seal and Corner Part for Weather Seal	2015-241085			
KU-3100 PCT	Hydrogenated Block Copolymer	PCT/JP2016/053527			
KU-3100 JP	Hydrogenated Block Copolymer	2016-537569			
KU-3100 TW	Hydrogenated Block Copolymer	105104115			
KU-3200 JP	Stretch Material, Film, Nonwoven Fabric	2016-119974			
KU-3300 PCT	Polyfarnesene and Method for Producing Same	PCT/JP2016/068257			
KU-3300 TW	Polyfarnesene and Method for Producing Same	105119847			
KU-3400 JP	Polyfarnesene, Rubber Composition Using Same, and Tire	2015-131237			
KU-3500 JP	Rubber Composition and Tire	2015-131799			
KU-3600 JP	Rubber Composition and Tire	2015-131800			
KU-3700 PCT	Polymer-Coated Particle, Resin Modifier, Rubber Composition and Tire	PCT/JP2016/075087			
KU-3700 TW	Polymer-Coated Particle, Resin Modifier, Rubber Composition and Tire	105127779			
KU-3800 PCT	Polymer-Coated Particle, Resin Modifier, Rubber Composition and Tire	PCT/JP2016/075088			
KU-3800 TW	Polymer-Coated Particle, Resin Modifier, Rubber Composition and Tire	105127780			

Amyris Ref	Title	Application No.	Patent Number	Issue Date	Expiration Date
KE- 100	Materials and Methods for Increasing Isoprenoid Production in Cells	US 10/835,516	US 7,129,392	2006-10-31	2020-07-31
KE- 100 D1	Use of Pseudogene Insertion Sites to Create Novel Traits in Transgenic Organisms	US 11/053,541	US 7,618,819	2009-11-17	2021-04-05
KE- 100 D2	Manipulation of Genes of the Mevalonate and Isoprenoid Pathways to Create Novel Traits in Transgenic Organisms	US 14/086,729	US 8,999,682	2015-04-07	2020-07-31

**Notes:**

The AM-6400 patent family is co-owned by Amyris and Total; all other AM patent families are owned by Amyris.

AR-100 patent families are in-licensed from Arkion (Bio-Technical Resources Division of Arkion Life Sciences LLC)

UC patent families are in-licensed from University of California

GV patent families are co-owned by Givaudan and Amyris

KU patent families are co-owned by Kuraray and Amyris

KE patent families are in-licensed from Kuehnle Agrosystems LLC



---

## **Exhibit 4**

---


# Consumer Brands Trademarks and Service Marks

Title	Image	Application Number	Application Date	Registration Number	Registration Title	Registration Date	Status	Brand
BEAUTY IS IN OUR BIOLOGY		86/527,684	02/06/2015	5,214,473	BEAUTY IS IN OUR BIOLOGY	05/30/2017	Reg/Drop	Biossance
BIOSSANCE		86/527,683	02/06/2015	5,214,472	BIOSSANCE	05/30/2017	Registered	Biossance
BIOSSANCE & Design		87/633,511	10/04/2017	5468468	BIOSSANCE & Design	05/15/2018	Registered	Biossance
BORN IN BERKELEY CALIFORNIA & Design		87/481,624	06/08/2017	5,551,894	BORN IN BERKELEY CALIFORNIA & Design	08/28/2018	Registered	Biossance
PIPETTE		88/228360	12/13/2018	6273314	PIPETTE	2021-02-16	Registered	Pipette
PLANT DERIVED SQUALANE & Design		87/481,618	06/08/2017	5,764,218	PLANT DERIVED SQUALANE & Design	05/28/2019	Registered	Biossance
PP PIPETTE (STYLIZED)		90/741651	05/28/2021		PP PIPETTE (STYLIZED)		Pending	Pipette
PP PIPETTE (STYLIZED)		88/471874	06/13/2019	6441723	PP PIPETTE (STYLIZED)	2021-08-03	Registered	Pipette
THE CLEAN ACADEMY BIOSSANCE & Design		88/982,249	06/24/2019	6,472,280	THE CLEAN ACADEMY BIOSSANCE & Design	08/31/2021	Registered	Biossance
THE CLEAN ACADEMY BY BIOSSANCE		88/980,911	06/24/2019	6,350,021	THE CLEAN ACADEMY BY BIOSSANCE	05/11/2021	Registered	Biossance
ATHENA'S SHIELD		97/560,343	08/23/2022		ATHENA'S SHIELD		Pending	MenoLabs
BIOLOGY BY NATURE. HUMAN BY DESIGN.		87/236,450	11/14/2016	5,292,847	BIOLOGY BY NATURE. HUMAN BY DESIGN.	09/19/2017	Reg/Drop	Biossance
4U BY TIA		97/490,180	07/06/2022		4U BY TIA		Allowed	4U By Tia
BARE YOUR SOL		97/645,630	10/24/2022		BARE YOUR SOL		Pending/Drop	Stripes
BEAUTY IN BEING		90/784,564	06/21/2021		BEAUTY IN BEING		Published	Rose Inc
BIOSSANCE CLEAN CREW (Stylized)		90/211,423	09/25/2020	6,599,046	BIOSSANCE CLEAN CREW (Stylized)	12/21/2021	Registered	Biossance
CLEAN CREW		90/211,384	09/25/2020	6,457,736	CLEAN CREW	08/17/2021	Registered	Biossance
COME AS YOU ARE		90/784552	06/21/2021		COME AS YOU ARE		Pending	JVN
DEW AS I DO		97/610,873	09/28/2022		DEW AS I DO		Allowed	Stripes
DIM (Logo)		90/366,121	12/08/2020	6,714,342	DIM (Logo)	04/26/2022	Registered	MenoLabs
EVENING WEAR		97/610,934	09/28/2022		EVENING WEAR		Allowed	Stripes
GODDESS GLOW BEAUTY COLLAGEN		90/394,455	12/18/2020	6,599,210	GODDESS GLOW BEAUTY COLLAGEN	12/21/2021	Registered	MenoLabs
GODDESS GLOW BEAUTY COLLAGEN (Logo)		90/398,746	12/21/2020	6,599,216	GODDESS GLOW BEAUTY COLLAGEN (Logo)	12/21/2021	Registered	MenoLabs
HAPPY FIBER		90/189,559	09/17/2020	6,577,827	HAPPY FIBER	11/30/2021	Registered	MenoLabs
HAPPY FIBER		90/189/559	09/17/2020	6577827	HAPPY FIBER	11/30/2021	Registered	MenoLabs
HAPPY FIBER (Logo)		90/352,195	12/01/2020	6599177	HAPPY FIBER (Logo)	12/21/2021	Registered	MenoLabs
HEMI15		97/773241	01/30/2023		HEMI15		Pending	4U By Tia
INSIDE ADDITION		97/611,185	09/28/2022		INSIDE ADDITION		Pending	Stripes

# Consumer Brands Trademarks and Service Marks

Title	Image	Application Number	Application Date	Registration Number	Title	Registration Date	Status	Brand
JVN		90/784559	06/21/2021		JVN		Pending	JVN
JVN		97/302716	03/09/2022		JVN		Pending	JVN
MENOCHILL		88/648,188	10/09/2019	6,103,708	MENOCHILL	07/14/2020	Registered	MenoLabs
MENOFIT		88/648,114	10/09/2019	6,103,706	MENOFIT	07/14/2020	Registered	MenoLabs
MENOFIT (Logo)		90/352,152	12/01/2020	6,477,605	MENOFIT (Logo)	09/07/2021	Registered	MenoLabs
MENOGLOW		88/648,068	10/09/2019	6,103,704	MENOGLOW	07/14/2020	Registered	MenoLabs
MENOGLOW (Logo)		90/352,076	12/01/2020	6,477,598	MENOGLOW (Logo)	09/07/2021	Registered	MenoLabs
MENOGUARD		88/648,165	10/09/2019	6,103,707	MENOGUARD	07/14/2020	Registered	MenoLabs
MENOLABS		88/648,011	10/09/2019	6,149,323	MENOLABS	09/08/2020	Registered	MenoLabs
MENOLIFE		88/648,220	10/09/2019	6,103,709	MENOLIFE	07/14/2020	Registered	MenoLabs
MIGHTY RICH		97/796,009	02/15/2023		MIGHTY RICH		Pending	Stripes
MISCELLANEOUS DESIGN (SALON CHAIR)		97/551971	08/17/2022		MISCELLANEOUS DESIGN (SALON CHAIR)		Pending	JVN
OH-MY-GLIDE		97/611,178	09/28/2022		OH-MY-GLIDE		Pending	Stripes
PIPETTE		90/741469	05/28/2021		PIPETTE		Pending	Pipette
PIPETTE		97/435747	05/31/2022		PIPETTE		Pending	Pipette
PIPETTE		88/975938	12/13/2018	5905428	PIPETTE	2019-11-05	Registered	Pipette
POWERED BY MOISTURIZING SQUALANE		97/551919	08/17/2022		POWERED BY MOISTURIZING SQUALANE		Pending	Pipette
PP PIPETTE (STYLIZED)		88/977163	06/13/2019	6060596	PP PIPETTE (STYLIZED)	2020-05-19	Registered	Pipette
ROSE INC.		87/983,777	05/12/2017	6,441,459	ROSE INC.	08/03/2021	Registered	Rose Inc
ROSE INC.		87/446,941	05/12/2017		ROSE INC.		Allowed	Rose Inc
ROSE INC.		87/984,004	05/12/2017	6,548,007	ROSE INC.	11/02/2021	Registered	Rose Inc
SOL QUEEN		97/645,638	10/24/2022		SOL QUEEN		Pending	Stripes
STRIPES		97/260,955	02/10/2022		STRIPES		Allowed	Stripes
THE COOL FACTOR		97/611,025	09/28/2022		THE COOL FACTOR		Pending	Stripes
THE CROWN PLEASER		97/611,135	09/28/2022		THE CROWN PLEASER		Pending	Stripes
THE DREAM DATE		97/611,202	09/28/2022		THE DREAM DATE		Pending	Stripes

# Consumer Brands Trademarks and Service Marks

Title	Image	Application Number	Application Date	Registration Number	Title	Registration Date	Status	Brand
THE COOL FACTOR		97/611,025	09/28/2022		THE COOL FACTOR		Pending	Stripes
THE CROWN PLEASER		97/611,135	09/28/2022		THE CROWN PLEASER		Pending	Stripes
THE DREAM DATE		97/611,202	09/28/2022		THE DREAM DATE		Pending	Stripes
THE FULL MONTY		97/611,117	09/28/2022		THE FULL MONTY		Pending	Stripes
THE NECK'S CHAPTER		97/611,222	09/28/2022		THE NECK'S CHAPTER		Pending	Stripes
THE POWER MOVE		97/610,950	09/28/2022		THE POWER MOVE		Allowed	Stripes
THE RESTING CLEAN FACE		97/611,098	09/28/2022		THE RESTING CLEAN FACE		Pending	Stripes
THE ROOT OF IT		97/611,154	09/28/2022		THE ROOT OF IT		Suspended	Stripes
THE SUPPORT SYSTEM		97/611,196	09/28/2022		THE SUPPORT SYSTEM		Pending	Stripes
TO MAMA, WITH LOVE		90/626217	04/06/2021		TO MAMA, WITH LOVE		Pending	Pipette
UNDER THE DRYER		97/397917	05/06/2022	7025682	UNDER THE DRYER	2023-04-11	Registered	JVN
VAG OF HONOR		97/611,166	09/28/2022		VAG OF HONOR		Pending	Stripes
VIVA VOLUME		98/075673	07/07/2023		VIVA VOLUME		Pending	MenoLabs
WELL RESTED		97/165,117	12/09/2021	6,948,089	WELL RESTED	01/10/2023	Registered	MenoLabs
WELL RESTED BY MENOLABS		90/189,589	09/17/2020	6,834,623	WELL RESTED BY MENOLABS	08/30/2022	Registered	MenoLabs
WELL RESTED BY MENOLABS (Logo)		90/352,230	12/01/2020	6,714,298	WELL RESTED BY MENOLABS (Logo)	04/26/2022	Registered	MenoLabs